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Abstract
This review presents recommended nomenclature for the biosynthesis of ribosomally synthesized
and post-translationally modified peptides (RiPPs), a rapidly growing class of natural products.
The current knowledge regarding the biosynthesis of the >20 distinct compound classes is also
reviewed, and commonalities are discussed.
1 Introduction
Natural products have played key roles over the past century in advancing our understanding
of biology and in the development of medicine. Research in the 20th century identified
many classes of natural products with four groups being particularly prevalent: terpenoids,
alkaloids, polyketides, and non-ribosomal peptides. The genome sequencing efforts of the
first decade of the 21st century have revealed that another major class is formed by
ribosomally synthesized and post-translationally modified peptides. These molecules are
produced in all three domains of life, their biosynthetic genes are ubiquitous in the currently
sequenced genomes1–8 and transcriptomes,9,10 and their structural diversity is vast.11 The
extensive post-translational/co-translational modifications endow these peptides with
structures not directly accessible for natural ribosomal peptides, typically restricting
conformational flexibility to allow better target recognition, to increase metabolic and
chemical stability, and to augment chemical functionality.
Because the common features of their biosynthetic pathways have only recently been
recognized, at present the nomenclature used in different communities investigating
subgroups of natural products of ribosomal origin is non-uniform, confusing, and in some
cases even contradictory. In order to define a uniform nomenclature, the authors of this
review engaged in a discussion over the summer and fall of 2011, and the consensus
recommendations of these discussions are presented herein. In addition, this review provides
an overview of the structures of and the biosynthetic processes leading to this large group of
natural products. Select examples are covered from bacteria, fungi, plants, and cone snails.
Post-translational in the context of this review is defined as any peptide chain modification
occurring after the initiation of translation.
Historically, ribosomally synthesized and post-translationally modified peptides have been
subdivided based on either the producing organisms (e.g. microcins produced by Gram-
negative bacteria)12 or their biological activities (e.g. bacteriocins).13 Unlike the
designations of the other four major classes of natural products listed above, an overarching
designation for these peptide natural products based on structural and biosynthetic
commonality is currently lacking. We propose that the biosynthetic pathway to these
compounds be referred to as Post-Ribosomal Peptide Synthesis (PRPS), in line with the
currently used designation of Non-Ribosomal Peptide Synthetase (NRPS) enzymes that
catalyze modular assembly line biosynthesis of peptide natural products.14,15 Furthermore,
we propose to designate the resulting ribosomally-synthesized and post-translationally-
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modified peptides as RiPPs, irrespective of their biological functions. The name “Post-
Ribosomal Peptides” was also considered as a logical extension of NRPs, but because this
designation would not capture the critical post-translational modifications, the name RiPPs
was ultimately preferred. Similarly, the name “Ribosomal Natural Products” was considered
but the resulting acronym, RNPs, was deemed too close to NRP, the acronym for non-
ribosomal peptides. Finally “Ribosomal Peptides” was discussed, but since confusion could
arise with peptides that make up the ribosome, RiPPs was again preferred. A size limit of 10
kDa is imposed on RiPPs to exclude post-translationally modified proteins. We note that a
small number of post-translationally modified natural metabolites are not well described by
this nomenclature because the final products lack any peptide bonds, such as the cofactor
pyrroloquinoline quinone (PQQ), and the thyroid hormones (see section 20).
1.1 Common features of RiPP biosynthesis
Nearly all compounds produced by PRPS are initially synthesized as a longer precursor
peptide, typically ~20–110 residues in length, encoded by a structural gene. In the past, the
various segments of this precursor peptide have been given different, sometimes conflicting
names for different RiPP subclasses (Table 1). We propose here a uniform naming scheme
in which the segment of the precursor peptide that will be transformed into the natural
product is called the core peptide or core region (Fig. 1). A distinction can be made with
respect to the unmodified core peptide (UCP) in the precursor peptide and the modified core
peptide (MCP) after the post-translational modifications. In most RiPPs, a leader peptide or
leader sequence is appended to the N-terminus of the core peptide that is usually important
for recognition by many of the post-translational modification enzymes and for export.16 In
some more rare examples such as the bottromycins (section 8),17–20 a leader peptide is not
attached at the N-terminus, but rather at the C-terminus of the core peptide and has been
termed a “follower” peptide. For eukaryotic peptides such as the cyclotides and
conopeptides discussed in this review, a signal sequence is often found N-terminal to the
leader peptide that directs the peptide to the specific cellular compartments where the post-
translational modifications will take place. Finally, some peptides have C-terminal
recognition sequences that are important for excision and cyclization.21–23 The unmodified
precursor peptide is generally designated “A” (encoded by the xxxA gene), but for some
classes different designations have been used historically (see discussion of individual RiPP
families). The modified precursor peptide prior to proteolytic removal of the leader peptide
can be abbreviated as mXxxA (e.g. mLanA; Fig. 1).
It is noteworthy that the leader peptide-guided strategy for the biosynthesis of RiPPs results
in highly evolvable pathways because many of the post-translational processing enzymes
recognize the leader peptide and are highly permissive with respect to mutations in the core
peptide. Indeed, the core regions are naturally hypervariable for subsets of the RiPP classes
discussed in this review,3,22,24–26 and engineering studies have further demonstrated the
plasticity of the biosynthetic enzymes.27–44 The relatively small number of enzymes
involved in the maturation pathways also facilitates natural evolution, and the multiplicity of
pathways towards the same types of chemical structures illustrates the convergent evolution
of efficient, ribosome-based biosynthetic strategies. Collectively, these features highlight the
potential evolutionary advantage of accessing high chemical diversity at low genetic cost.
We note that these very same attributes also prove advantageous with respect to genome
mining strategies as heterologous production of RiPPs is aided by short pathways and is not
limited by supply of precursors.
The explosion in sequence information has also revealed that many biosynthetic pathways
utilize common enzymes for a subset of the post-translational modifications. For instance,
the Ser/Thr dehydratases involved in the biosynthesis of lanthi onine-containing peptides
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(lanthipeptides) are also used in the biosynthetic pathways to the proteusins,45 thiopeptides,
and some linear azole-containing peptides (LAPs),44,46–49 while some of the enzymes
involved in oxazol(in)e and thiazol(in)e formation in thiopeptides46–50 are also used for the
biosynthesis of LAPs50–52 and bottromycins17–20 and are also often found in cyanobactin
biosynthetic gene clusters.21 Similarly, genes encoding radical-SAM dependent
methyltransferases are found in the biosynthetic gene clusters of thiopeptides,46
proteusins,45 and bottromycins.17–20 Thus, acquisition of new post-translational
modification enzymes appears to drive evolution to new structures. On the other hand, some
post-translational modifications appear to have evolved convergently, such as the different
ways to achieve head-to-tail (N-to-C) cyclization in the cyanobactins,53 amatoxins,54
circular bacteriocins,55 and cyclotides,56 and the different ways in which thioether crosslinks
are formed in various classes of lanthipeptides.57 Post-translational modifications involving
Cys residues occur especially frequently in RiPPs. Sulfur chemistry converts the thiols of
cysteines to disulfides (cyclotides, conopeptides, lanthipeptides, cyanobactins, lasso
peptides, sactipeptides, and glycocins), thioethers (lanthipeptides, sactipeptides, phalloidins,
some thiopeptides), thiazol(in)es (thiopeptides, LAPs, cyanobactins, bottromycins), and
sulfoxides (lanthipeptides, amatoxins). Additional common features are macrocyclization to
increase metabolic stability and decrease conformational flexibility, and modifications to the
N- and C-termini to limit the susceptibility to degradation by exoproteases.
Although the details of recognition of leader peptides by the biosynthetic enzymes are still
mostly unknown, many leader peptides have a propensity to form α-helices,58–64 either in
solution or when bound to the biosynthetic proteins.65,66 The leader peptides are thought to
play multiple roles in post-translational modification, export, and immunity. Furthermore,
several pieces of evidence suggest that different biosynthetic enzymes in a pathway
recognize different segments of the leader peptides.59,64,67,68 Leader peptide removal can
take place in one proteolytic step or in multiple proteolytic steps. In regards to the
numbering of the residues of the leader peptide, it is recommended to count backwards from
the final cleavage site and add a minus sign before the number, e.g. the last residue that is
not incorporated in the final RiPP is numbered −1 and counting then commences −2, −3 etc
towards the N-terminus (Fig. 1). Similarly, C-terminal recognition sequences/follower
peptides can be numbered with a plus sign from the site of final cleavage (e.g. the N-
terminal residue of the C-terminal recognition sequence would be numbered +1, Fig. 1)
counting up from this site towards the C-terminus. Counting schemes in the case of multiple
core peptides and recognition sequences (e.g. in the cyanobactins, cyclotides, and orbitides)
are case dependent.
The sections below briefly discuss the salient features of these various compound classes
including their defining structural motifs, common biosynthetic pathways, subdivisions into
subclasses, and recommendations regarding nomenclature. This review covers most
bacterial RiPPs that have been identified as well as select examples from fungi (amatoxins
and phallotoxins), plants (cyclotides and orbitides), and metazoans (conopeptides from cone
snails). Not covered, but often made by a similar biosynthetic logic if they are post-
translationally modified, are defensins69–71 and the venom peptides from insects and
reptiles.72–75
2 Lanthipeptides
2.1 Biosynthesis
First reported in 1928,76 nisin is one of the longest known RiPPs, but its structure was not
elucidated until 1971 (Fig. 2A).77 It contains the meso-lanthionine and 3-methyllanthionine
residues that define the lanthipeptide (for lanthionine-containing peptides) class of
molecules. Lanthipeptides that have antimicrobial activity are called lantibiotics.78
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Lanthionine (Lan) consists of two alanine residues crosslinked via a thioether linkage that
connects their β-carbons; 3-methyllanthionine (MeLan) contains one additional methyl
group (Fig. 2B). The ribosomal origin of lanthionine-containing peptides was first proposed
in 197079 and experimentally verified in 1988 when the biosynthetic gene cluster for
epidermin was sequenced.78 Shortly thereafter, the precursor genes for nisin,80,81 subtilin,82
and Pep583 were identified. The biosynthetic genes have been designated the generic locus
symbol lan, with a more specific genotypic designation for each lanthi-peptide member
(e.g., nis for nisin,81 gar for actagardine,84 mrs for mersacidin,85 cin for cinnamycin86). The
Lan and MeLan residues are introduced in a two-step post-translational modification
process. In the first step, Ser and Thr residues in the precursor peptide are dehydrated to
dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues, respectively, usually via a
phosphorylated intermediate (Fig. 2B).87–89 The thioether crosslinks are formed
subsequently via a Michael-type addition by Cys residues onto the dehydro amino acids.
At present lanthipeptides are classified into four different classes depending on the
biosynthetic enzymes that install the Lan and MeLan motifs (Fig. 3).57 For class I
lanthipeptides, the dehydration is carried out by a dedicated dehydratase generically called
LanB,90–93 with a more specific designation for each lanthipeptide (e.g. NisB for nisin).
Cyclization of class I lanthi-peptides is catalyzed by a LanC cyclase.94–96 Several pieces of
evidence suggest these proteins form a multienzyme complex.97 For class II,98,99 III,88 and
IV89 lanthipeptides, dehydration and cyclization is carried out by bifunctional lanthionine
synthetases. The class II LanM lanthionine synthetases have N-terminal dehydration
domains that do not display sequence homology with other enzymes in the databases.
However, the C-terminal cyclization domains have homology with the LanC cyclases of
class I (Fig. 3). For both class III and IV lanthipeptides, dehydration is carried out by
successive actions of a central kinase domain and an N-terminal phosphoSer/phosphoThr
lyase domain,89,100 but the class III and IV synthetases differ in their C-terminal cyclization
domains (Fig. 3).101 Although these domains show sequence homology to each other as well
as to the LanC proteins, three metal binding residues95,102 that are fully conserved in class I,
II, and IV cyclases are absent in the class III cyclization domains.101 A subset of class III
enzymes generates an additional carbon–carbon crosslink, putatively by attack of the
initially generated enolate onto a second dehydroalanine (Fig. 2B). The structure thus
formed is called a labionin (Lab), first detected in the labyrinthopeptins.103
Lanthipeptide biosynthetic enzymes have demonstrated low substrate specificity, allowing
substitutions of those residues in the core peptide that are not post-translationally modified
with both proteinogenic27–30,33–35,105–109 and non-proteinogenic amino acids.34,110,111 The
enzymes that generate the characteristic cross-links are dependent on the presence of the
leader peptide,59,63,78,93,95,99,112–116 but several of the enzymes that install other post-
translational modifications do not require the leader peptide.117–119 Furthermore, non-
lanthipeptide sequences attached to LanA leader peptides have been modified by the
lanthipeptide biosynthetic machinery.92,120–123 For the class II lantibiotic lacticin 481116,124
and the class I lantibiotic nisin,125 it has been demonstrated that the leader peptide does not
need to be attached to the core peptide. The results of these studies better fit a model in
which leader peptide binding results in a shift in the equilibrium between an inactive and
active form of the synthetase towards the latter, rather than models in which the leader
peptide pulls the core peptide through the active site or in which leader peptide binding
induces a conformational change.59,116
2.2 Structure and biological activities of lanthipeptides
Recent years have revealed that lanthionine-containing peptides can have functions beyond
antimicrobial activities,101,104,126 and therefore the name lantipeptide was initially
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introduced for all lanthionine and methyllanthionine containing peptides,89 with lantibiotics
forming a large subgroup. As described above, we revise the term lantipeptide here to
lanthipeptide as a more faithful representation for lanthionine-containing peptides regardless
of their biological activities.
Nisin (class I) is the best studied lantibiotic and has been used in the food industry to combat
food-borne pathogens for more than 40 years.127 It binds to lipid II, an essential intermediate
in peptidoglycan biosynthesis, resulting in inhibition of cell wall biosynthesis and pore
formation.128,129 Other notable lanthipeptides include the class II lantibiotic actagardine, a
semi-synthetic derivative of which is in development against Clostridium difficile,84 the
class II lantibiotic duramycin that binds phosphatidylethanolamine and is being evaluated
for treatment of cystic fibrosis,130 and labyrinthopeptin, a class III compound with
antiallodynic activity (Fig. 4).103 An interesting group of class II lantibiotics are the two-
component peptides such as lacticin 3147 and haloduracin.131–134 These peptides
synergistically kill bacteria with the α-peptide binding to lipid II.135,136 The β-peptide is
then believed to bind to the complex formed between the α-peptide and lipid II and induce
pore formation.137
The first lanthipeptides shown to have functions other than antimicrobial agents were the
morphogenetic peptides SapB and SapT from streptomycetes.101,126 These peptides are
believed to function as biosurfactants during the formation of aerial hyphae.139
Lanthipeptides are defined by the presence of the characteristic (Me)Lan residues, but as
many as 15 other post-translational modifications have been documented,57,128,138 with
additional modifications likely to be uncovered in the future. Unlike (Me)Lan, Dha, and Dhb
formation, these additional modifications appear not to rely on the presence of a leader
peptide for the examples investigated thus far.117–119,140
Genome database mining has illustrated that the biosynthetic genes for lanthipeptides are
distributed much more widely than the Firmicutes and Actinobacteria to which biosynthesis
of these compounds was believed to be restricted. Their genes are now also found in certain
bacteroidetes, chlamydiae, proteobacteria, and cyanobacteria.26,89,141,142 In all, over 90
lanthipeptides are known with hundreds more identified in genomes.2,3,26,141–143
2.3 Specific recommendations for the lanthipeptide family
The name lanthipeptides describes all lanthionine- and methyllanthionine-containing
peptides made by PRPS. Lantibiotics form a large subgroup with antimicrobial activities.
The gene designations for the various post-translational modification enzymes involved in
lanthipeptide biosynthesis are well established and we recommend continued use of the
generic name LanA for the precursor peptide, LanBC for the dehydratases and cyclases of
class I lanthipeptides, and LanM and LanL for the bifunctional enzymes involved in the
biosynthesis of class II and IV compounds, respectively. The class III bifunctional enzymes
should be called LanKC irrespective of whether they result in formation of labionines or
lanthionines because at present the final products cannot be predicted from the sequences of
the synthetases.104,144 The suffix-peptin is recommended for naming new members of class
III peptides.104,144
Further recommendations are the continued use of LanP for Ser proteases that remove part
of or the entire leader peptide, LanT for transporters that secrete the lanthipeptides (with or
without an N-terminal Cys protease domain), LanEFG for the transporters that are involved
in self-resistance, LanI for additional immunity proteins, and LanKR for two-component
response regulators. With respect to the enzymes that install the less common PTMs, LanD
should be used for the enzymes that oxidatively decarboxylate C-terminal Cys residues,145
LanO for various oxidation enzymes,84,140,146 LanX for hydroxylases,118,147 and LanJ for
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enzymes that convert Dha to D-Ala.148 This recommendation leaves only a small series of
letters remaining (lanHNQSWYZ), some of which have already been used to name
individual, non-common genes in lanthipeptide gene clusters.149 Hence, we recommend the
use of a five-letter designation, such as that used for lanKC, for genes that may be
uncovered in future studies and that have no sequence homology with currently known
lanthipeptide biosynthetic genes.
3 Linaridins
Linaridins are a recently discovered family of RiPPs that share the presence of thioether
crosslinks with the lanthipeptide family but that are generated by a different biosynthetic
pathway. Cypemycin is the founding member of the family and it was considered a
lanthipeptide because of the presence of a C-terminal aminovinyl cysteine (Fig. 5).150 These
same structures are found in several lantibiotics such as epidermin and mersacidin and are
believed to be generated by Michael-type addition of an oxidatively decarboxylated C-
terminal Cys onto a Dha,151 with the latter formed by dehydration of Ser. However, when
the biosynthetic gene cluster of cypemycin was identified, it became clear that none of the
four types of lanthipeptide dehydratases were present in the cluster.152 Furthermore, the
sequence of the core peptide illustrates that the AviCys structure is formed from two Cys
residues. Based on these differences from the biosynthetic route to AviCys in lanthipeptides,
cypemycin and related peptides found in the genome databases6,152,153 have been classified
as a separate group, the linaridins. If future research identifies linaridins containing Lan and/
or MeLan, it may be that linaridins are better classified as another subclass of the
lanthipeptides, but as long as that is not the case, they are grouped separately.
4 Proteusins
Polytheonamides (Fig. 6) were reported in 1994 as extremely cytotoxic constituents of a
Japanese Theonella swinhoei sponge,154 which harbors a large diversity of symbiotic
bacteria.155 These initial studies and a structural revision in 2005 by the same group156
established the compounds as highly complex 48-mer peptides containing, in addition to an
unprecedented N-acyl moiety, an unusually large number of nonproteinogenic residues,
including many tert-leucine and other C-methylated amino acids. One of the most
interesting features is the presence of multiple D-configured units that are localized in near
perfect alternation with L-amino acids, reminiscent of the nonribosomally produced linear
gramicidins.157 Like these compounds, polytheonamides form membrane channels, which is
at least in part the basis of their cytotoxicity.158 Channel formation occurs by adoption of a
β-helical secondary structure and directional insertion into the membrane aided by the
lipophilic N-acyl unit.158,159 However, unlike the bimolecular gramicidin pores, the much
larger polytheonamides are able to span the entire membrane and thus form minimalistic ion
channels as single molecules. Because of the highly modified polytheonamide structures it
was generally assumed that they are nonribosomal peptides and, as such, the largest known
members of this family. Recently, however, metagenomic studies were conducted on the
sponge involving screening of a ~1 million clone DNA library, which revealed that
polytheonamides are biosynthesized via a ribosomal pathway.45 Such an origin is notable,
since it implies the existence of 48 postribosomal modification steps excluding removal of
the leader region, making polytheonamides the most extensively modified RiPPs known to
date. Particularly noteworthy is the regiospecific epimerization of 18 structurally diverse L-
amino acids, which suggests that there is no significant biochemical limitation to the stereo-
and regiospecific biosynthesis of configurationally mixed ribosomal products. These
structural peculiarities as well as the unusually large leader region of the precursor (see
below) classified polytheonamides as members of a new RiPP family, termed proteusins.
The metagenomic study also showed that an as-yet uncultivated bacterial symbiont of the
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sponge is the actual producer, highlighting the potential of environmental bacteria as sources
of structurally novel RiPPs.45
4.1 Biosynthesis and structural classifications of proteusins
Biosynthesis of polytheonamides involves a precursor protein (PoyA) with a large leader
region that exhibits similarity to nitrile hydratase-like enzymes. By coexpressing the
precursor gene with a variety of genes for posttranslational modification, the function of
several modifying enzymes was established.45 Remarkably, in a first step a single
epimerase, PoyD, generates most, and possibly all, D-residues. The enzyme is homologous
to members of the radical S-adenosyl methionine superfamily160 and likely acts by
abstracting an α-hydrogen to form a stabilized amino acyl radical. Hydrogen donation from
the backside would then result in epimerization. The source of the second hydrogen is
currently unknown. Epimerization occurs unidirectional, which is in contrast to the
equilibrium-forming, as-yet uncharacterized epimerases associated with, e.g., several
modified peptides from animals.161 Only few homologues of PoyD are currently listed in
GenBank. All contain a characteristic N-terminal domain-like region of unknown function
and are associated with nitrile hydratase-like precursors. The second step in polytheonamide
biosynthesis is dehydration of a Thr residue that seems to be the biosynthetic source of the
unusual N-acyl residue (Fig. 7A).45 This reaction is performed by PoyF, an enzyme
resembling the N-terminal dehydratase domain of LanM-type class II bifunctional
lanthionine synthetases (see section 2). Further conversion to the N-acyl unit likely proceeds
via net t-butylation catalyzed by one or more class B162 radical-SAM methyltransferases
(PoyB and/or C are candidates), which would add a total of four methyl groups to the methyl
group originating from Thr (Fig. 7A). Hydrolytic removal of the leader region would then
generate an enamine moiety that would spontaneously form the α-keto unit found in
polytheonamides, similar to the ketone generation at the N-terminus of Pep5-like
lanthipeptides.83,140,146,163 Regiospecific generation of the 8 N-methylated Asn residues
was shown to be catalyzed by a single N-methyltransferase, PoyE.45 A general hallmark of
the pathway is the extremely streamlined gene cluster that encodes several highly iterative
enzymes (Fig. 7B). For all 48 modifications, only 6 enzyme candidates encoded in a 14 kb
cluster were identified. However, it has to be tested whether the remaining as-yet
uncharacterized modifications (4 hydroxylations and 17 C-methylations) are indeed
catalyzed by enzymes belonging to the cluster or whether additional genes might be located
elsewhere on the symbiont genome. If the cluster is sufficient for biosynthesis, the putative
Fe(II)/α-keto-glutarate-dependent oxygenase PoyI and the two radical-SAM
methyltransferase-like enzymes PoyC and PoyD would be candidates for these 23
transformations.
Prior to the discovery of the polytheonamide gene cluster, the existence of a new RiPP
family with unusually long nitrile hydratase-like leader peptides (NHLP) sequences was
postulated based on bioinformatic analyses.3 These sequences are found in genome
sequences of diverse bacteria, although the identity of the peptides was unknown. This
prediction demonstrates the power of in silico genome mining methods to discover new
RiPP classes. In addition to NHLP homologues, a second precursor type that contains a
leader region resembling Nif11 nitrogen-fixing proteins (N11P) was identified in the
bioinformatic study. For both groups of leader peptide, one or multiple radical-SAM genes
(predicted to encode amongst others, epimerases, and C-methyltransferases) are frequently
present in the biosynthetic gene clusters.5 Thus, although polytheonamides are currently the
only known characterized proteusins, a unifying feature of this family seems to be NHLP or
N11P sequences and modifications involving radical-SAM enzymes. Interestingly, the
N11P-like leader peptides are also used to produce lanthipeptides in marine
cyanobacteria.3,26 Radical-SAM proteins are also used for the biosynthesis of two other
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RiPP families, bottromycins and sactipeptides, and bio-informatic analyses suggest that
these radical-SAM mediated transformations may be as common as the ubiquitous (cyclo)
dehydration reactions discussed in sections 5–8.5
4.2 Specific recommendations for the proteusin family
One common feature at the genetic level is the conspicuous and characteristic nitrile
hydratase- or Nif11-like leader peptide of the precursor gene. Similar to other RiPPs it is
recommended to use the descriptor “A“ for the precursor peptide. Regarding
posttranslational modification, it is currently premature to propose unifying
recommendations, since polytheonamides are the only members known to be associated
with this family, and there is generally little overlap with the biosynthetic enzymes of other
RiPP types.
5 Linear azol(in)e-containing peptides (LAPs)
5.1 Historical perspective
The earliest work on the linear azol(in)e-containing peptides (LAPs) dates back to at least
1901 with the observation that certain pathogenic isolates of streptococci secrete a factor
responsible for what later became known as the β-hemolytic phenotype.164,165 Despite a
flurry of work carried out on the hemolytic streptococci in the opening decade of the 20th
century, studies in the 1930s provided the first significant insight into the β-hemolytic factor,
streptolysin S (SLS).166,167 Because of the problematic physicochemical properties of SLS,
it was not until 2000 that researchers realized the defining chemical attributes of this RiPP
subfamily.168 This realization was enabled by a rapid advancement in the understanding of
the biosynthesis of another LAP member, microcin B17, the first RiPP to have its
biosynthesis reconstituted in vitro (vide infra).50,51 To this day, the exact chemical structure
of SLS remains elusive. However, the classification of SLS as a LAP and an integral
component of the pathogenic mechanism of Streptococcus pyogenes was confirmed by a
series of recent genetic and biochemical studies.7,37,169 Bioinformatic and biochemical
investigations have shown that a number of pathogens from the Firmicutes phylum contain
SLS-like gene clusters, including lineage I strains of Listeria monocytogenes and
Clostridium botulinum.170–172
5.2 LAP biosynthesis
LAPs are decorated with various combinations of thiazole and (methyl)oxazole
heterocycles, which can sometimes also be found in their corresponding 2-electron reduced
azoline state (Fig. 8).52 As demonstrated for microcin B17 in 1996, the azol(in)e
heterocycles derive from cysteine, serine, and threonine residues of a ribosomally
synthesized precursor peptide.51 The critical components in LAP biosynthesis are the
inactive precursor peptide (referred to as “A”) and the heterotrimeric synthetase complex
comprised of a dehydrogenase (B) and cyclodehydratase (C/D). In many LAP biosynthetic
gene clusters, the C–D proteins are fused in a single polypeptide, highlighting the
importance of their enzymatic collaboration.52,173 The first step in LAP biosynthesis is
substrate recognition, driven through an interaction of the N-terminal leader peptide of the
precursor (Fig. 8 and 9), which remains unmodified.37,58 After formation of the enzyme-
substrate complex, ATP-dependent cyclodehydration occurs with the expulsion of water
from the preceding amide carbonyl giving rise to an azoline heterocycle.173 ATP is used in
this step to phosphorylate the amide oxygen to facilitate the elimination of a water
equivalent from the substrate.173 In a second step, a flavin mononucleotide (FMN)-
dependent dehydrogenase oxidizes a subset (sometimes all) of the azolines to the aromatic
azole heterocycles.51,174 A typical LAP will then undergo proteolytic processing to remove
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the leader peptide with subsequent transport out of the producing cell by a dedicated ATP
binding cassette (ABC) type transporter.
While the defining feature of a LAP is the genetically and biochemically conserved
installation of azol(in)e rings on non-macrocyclized natural products (as opposed to the
cyanobactins and thiopeptides discussed in the following sections), other post-translational
modifications are often found. These ancillary tailoring modifications include acetylation,
methylation, and dehydration.7,44,52
5.3 Structures and bioactivities of LAPs
Aside from microcin B17 and SLS, a number of additional LAPs have been identified by
mining publicly available genome sequences. Only those LAPs with a fully elucidated
chemical structure are discussed here, but it is probable that trifolitoxin and some nitrile
hydratase/nif11-derived natural products are also LAPs.3,175,176 Goadsporin is produced by
Streptomyces sp. TP-A0584 and contains two thiazoles, four (methyl)oxazoles, two
dehydroalanines, and an acetylated N-terminus (Fig. 9).177,178 The genes responsible for the
chemical maturation of this LAP were reported in 2005.44 Goadsporin provides a link
between the LAP family and the lanthipeptides as the dehydroalanines are generated by
proteins with homology to the class I lanthipeptide dehydratases (LanBs). The precise
biological target(s) of goadsporin has not yet been determined, but it is known to induce
secondary metabolism and morphogenesis in a wide variety of streptomycetes. Goadsporin
also exhibits antibiotic activity against Streptomyces, including potent activity against
Streptomyces scabies, the causative agent of potato scab.
Plantazolicin (PZN) was predicted by bioinformatics to be an excreted metabolite from the
soil-dwelling microbe Bacillus amyloliquefaciens FZB42.7 Genetic evaluation of the PZN
biosynthetic pathway, molecular weight determination, and confirmation of antibiotic
activity were reported in early 2011.179 Later that year, two groups independently reported
the structure of PZN.180,181 Cyclodehydration was shown to precede dehydrogenation in
vivo,181 as hypothesized from earlier work on microcin B17 and azol(in)e-containing
cyanobactins.51,182–184 PZN has striking antimicrobial selectivity for Bacillus anthracis, and
its biosynthetic genes are found in several other Gram-positive bacterial species.181
5.4 Relationship to other RiPP subfamilies
The genes responsible for installing the azol(in)e heterocycles are the defining characteristic
of the LAP subfamily of RiPPs. It is important to note that the BCD heterocycle-forming
genes are genetically similar with respect to biochemical function to those that install
heterocycles on macrocyclized RiPPs (e.g. the thiopeptides, cyanobactins, and bottromycins,
vide infra).50,52,185
5.5 Specific recommendations for the LAP family
To avoid future confusion with the letter assignment of biosynthetic genes for LAPs, we
recommend that “A” always be reserved for the precursor peptide, regardless of its location
within a biosynthetic gene cluster. Likewise, we encourage the use of “C/D” for the
cyclodehydratase and “B” for clusters that encode a dehydrogenase.
6 Cyanobactins
6.1 Structures and biosynthesis
In the 1970s, growing interest in bioactive components of marine animals prompted Ireland
and Scheuer to investigate the tunicate Lissoclinum patella, collected on tropical coral reefs
in the Western Pacific. In 1980, they reported the structure elucidation of two small,
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cytotoxic peptides, ulicyclamide and ulithiacyclamide, revealing a then-unprecedented
combination of chemical features, including N-to-C macrocyclization and heterocyclization
to form thiazol(in)e and oxazoline motifs (Fig. 10).186 L. patella harbors an abundant,
uncultivated symbiotic cyanobacterium, Prochloron didemni, leading the authors to propose
that symbiotic cyanobacteria make the compounds. Indeed, 12 years after this initial report,
the homologous compound westiellamide was isolated from cultivated cyanobacteria and
from ascidians.187,188 Overall, approximately 100 related compounds were described from
marine animals and cultivated cyanobacteria as of the early 2000s.185 Compounds in the
group were N-to-C macrocyclic, and many (but not all) were further modified by
heterocyclization. Several family members were prenylated on Ser, Thr, or Tyr, while others
were N-methylated on His.
The family relationship of these structurally and functionally diverse metabolites was not
universally appreciated until their gene clusters were sequenced. Genes were reported for the
patellamide group in 200521 and for ulithiacyclamide itself in 2006,25 confirming that the
“animal” compounds were in fact produced by P. didemni.21,189 Biosynthetic genes from
many different free-living and symbiotic cyanobacteria have since been reported, leading to
the proposal for a family name: cyanobactins (Fig. 10).32,64,190–195 Cyanobactins are
defined as N–C macrocyclic peptides encoded on a precursor peptide (designated as “E”, as
in PatE in patellamide biosynthesis), with proteolytic cleavage and macrocyclization
catalyzed by homologous serine proteases “A” and “G”, as in PatA and PatG.32,185,196
Optional, but widely-occurring, cyanobactin biosynthetic proteins include “D”, as in PatD,
the cyclodehydratase from the patellamide pathway; “F”, as in LynF, the tyrosine prenyl-
transferase from the lyn pathway; and conserved proteins of unknown function (“B” and
“C”). Additional elements include thiazoline/oxazoline dehydrogenases that aromatize the
heterocycles to thiazoles and oxazoles, methyltransferases, and several other uncharacterized
proteins. Of note, the D cyclo-dehydratase consists of the C–D domains found in LAP
biosynthesis (vide supra), and the azoline dehydrogenase is often, although not always, part
of the G protein and is homologous to the dehydrogenase referred to as “B” in the LAP
family.
About 200 cyanobactins have been identified, mostly via traditional chemical methods but at
least one-third by genome mining.64,185,196 All known cyanobactins derive from
cyanobacteria (or marine animals, where a cyanobacterial origin is likely) and are between
6–20 amino acids in length. Phylogenetic analysis has grouped the gene clusters into several
families that are predictive of the resulting chemical structures.64 Other types of N-to-C
macrocyclic peptides (circular peptides) abound in nature and include the cyclotides and
orbitides from plants,197,198 the amatoxins and phallotoxins from fungi,22,199 and circular
bacteriocins200 among others (see their respective sections in this review). However, these
compounds are so far not known to be produced using PatA, PatG, and PatE-like proteins,
and they contain different secondary modifications. Cyanobactin gene clusters have been
identified only in cyanobacteria to date, and evidence suggests that they might be present in
~30% of cyanobacterial strains.191,192 However, it is likely that cyanobactins exist in other
organisms as well. For example, structurally related peptides such as telomestatin are well
known from Streptomyces spp. These compounds are head-to-tail cyclized and contain
heterocycles, but, in contrast to known cyanobactins, multiple heterocycles are found in
tandem, some of which derive from non-proteinogenic amino acids such as β-
hydroxytyrosine. Recently, a gene cluster for the telomestatin family compound YM-216391
was reported.201 Interestingly, while YM-216391 is made by LAP-like cyclo-dehydratases,
the route to macrocyclization is convergent and utilizes different machinery.
Biosynthesis of cyanobactins begins with the E-peptide, which contains at minimum a leader
peptide, an N-terminal protease recognition sequence, a core peptide, and a C-terminal
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recognition sequence (Fig. 11).21 Both recognition sequences are generally 4–5 amino acids
in length. Often, more than one core peptide (up to 3 thus far) is encoded on a single E-gene;
in these cases, each core peptide is flanked by conserved N- and C-terminal recognition
sequences.64 If a D-protein (cyclodehydratase) is present, this protein acts first by
regioselective modification of Cys, Ser, and/or Thr residues to form oxazoline and
thiazoline.183,184 The E-peptide substrate is helical,60 presumably facilitating its interaction
with D,58 and a short sequence element in the E leader peptide is diagnostic of heterocycle
formation.64 Subsequently, other modifications take place. The A protease clips off the N-
terminal recognition sequences, leaving a free amine for macrocyclization.53 The G protease
then cleaves at the C-terminal recognition sequence and catalyzes C–N
macrocyclization.53,202 An X-ray structure of the macrocyclase domain of PatG
demonstrated that it has a subtilisin-like fold but contains insertions not found in these
proteases.203 Furthermore, the structure of an acyl enzyme intermediate in which the peptide
to be cyclized is bound to an active site Ser residue provides insights into the macro-
cyclization process.203 At present, it appears that prenylation occurs after macrocyclization,
and only if a certain type of F gene is present.204 The F-protein is usually specific for
dimethylallylpyrophosphate,204 but evidence suggests that longer isoprenoids can be
incorporated in some cyanobactins.192 When multiple core peptides are present on a single
E-precursor, they are all modified into cyanobactin products,21 and multiple E genes are
often found in single organisms or pathways.64 Cyanobactins often contain D-amino acids,
which arise spontaneously because of their adjacency to azol(in)e residues.32,205 Like the
biosynthetic enzymes discussed for many other compound classes in this review, the
cyanobactin biosynthetic enzymes are promiscuous and accept diverse proteinogenic and
non-proteinogenic substrates in vivo and in vitro.25,202,204,206
Cyanobactins represent an enormous array of sequence and functional group diversity, and
many different biological activities have been attributed to the molecules, including anti-
cancer, antiviral, anti-protease, and antibiotic activity.185,207 Notably, several compounds
exhibit selective toxicity to certain human cancer cell lines,207,208 some potently block the
human multidrug efflux pump, P-glycoprotein,209,210 and many cyanobactins are known for
their ability to bind transition metals.207,211,212
6.2 Specific recommendations for the cyanobactin family
It is recommended that the nomenclature for proteins in this group be based upon the
precedent of the patellamide pathway. Therefore, the defining peptides are precursor peptide
(E), N-terminal protease (A), and C-terminal protease (G). Other commonly occurring
proteins in this group include cyclodehydratase (D), prenyltransferase (F), and hypothetical
proteins (B and C).
7 Thiopeptides
Thiopeptides were first reported in the late 1940s with the isolation of a micrococcin,213 and
have since burgeoned into a family of roughly 100 metabolites, a few of which are
represented in Fig. 12A. To date, the majority of thiopeptides are produced by
Actinobacteria, but several have been obtained from Firmicutes, including those from the
Bacillus and Staphylococcus genera.214–216 Also referred to as thiazolyl peptides or
pyridinyl polythiazolyl peptides, the thiopeptides typically feature a highly modified peptide
macrocycle bearing several thiazole rings and often possess multiple dehydrated amino acid
residues (for a review, see214). A defining feature of the thiopeptide macrocycle is a six-
membered nitrogenous ring that can be present in one of three oxidation states: a piperidine,
dehydropiperidine, or pyridine. Further architectural complexity is achieved in some
thiopeptides by the addition of a second macrocycle to incorporate a tryptophan-derived
quinaldic acid or an indolic acid residue, such as those found in thiostrepton A and
Arnison et al. Page 11
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
nosiheptide (Fig. 12A).217,218 For over sixty years following the discovery of micrococcin,
it was uncertain whether thiopeptides derived from the extensive post-translational
modification of ribosomally-synthesized precursor peptides, or, instead, if their polypeptide
backbones were the products of nonribosomal peptide synthetases. A series of publications
in early 2009 revealed the biosynthetic gene clusters of five thiopeptides, leading to the
formal recognition that these metabolites are indeed RiPPs.46–49
7.1 Structural classifications of thiopeptides
Structurally, the thiopeptides can be classified into five series, based on the oxidation state
and substitution pattern of the central nitrogenous heterocycle (Fig. 12B). This classification
scheme originates from an initial proposal by Hensens in 1978, and was later elaborated by
Bagley to accommodate a more diverse set of metabolites – nearly 80 members by
2005.214,219 Series a thiopeptides, exemplified by certain thiopeptins, present the core
heterocycle as a fully saturated piperidine.219,220 Series b is classically represented by
thiostrepton A and its dehydropiperidine ring.221 Series c, thus far, is comprised of a single
entry, Sch 40832, in which the core nitrogen heterocycle is contained within an
imidazopiperidine.222 The trisubstituted pyridine ring, in micrococcin P1 and other series d
metabolites, is the most frequently encountered scaffold among the thiopeptides.214,223,224
The final sub-family, series e, also contains a pyridine, but possesses a hydroxyl group at the
fifth position of the ring, as can be observed in nosiheptide (Fig. 12A).225,226 All members
of the series a–c thiopeptides contain a second macrocycle in which a quinaldic acid, 4-(1-
hydroxyethyl)quinoline-2-carboxylic acid, links one side chain from the core macrocycle to
the core peptide N-terminus (e.g. thiostrepton A, Fig. 12A). In an analogous fashion, series e
metabolites also harbor a second macrocycle, with the distinction that two of the core
macrocycle’s side chains are connected to an indolic acid residue.
7.2 Biological activities of thiopeptides
Varied biological activities are attributed to thiopeptides, yet these RiPPs are perhaps best
known for their antibacterial properties. Although thiopeptides are potent inhibitors of
Gram-positive bacterial growth, little effect is generally exerted upon Gram-negative
bacteria. This spectrum of antibacterial activity is attributed to an inability of thiopeptides to
penetrate the outer membrane of Gram-negative species, since in vitro studies of thiopeptide
function often employ the biochemical targets from Escherichia coli.227–230 Two major
modes of antibacterial action are commonly reported for the thiopeptides, both of which
impede protein synthesis. The first, observed of thiostrepton A, nosiheptide, micrococcin P1,
and several others, results from a direct interaction with the prokaryotic 50S ribosomal
subunit.231–233 These thiopeptides bind near the GTPase-associated center that engages a
number of translation factors during initiation and elongation.234–236 Structural studies
revealed that thiopeptides bind to a cleft between the ribosomal protein L11 and the 23S
rRNA, and the precise intermolecular interactions differ according to the exact structural
features of the thiopeptide.231,237 Complexation of the ribosome and a thiopeptide disrupts
the conformational changes ordinarily communicated from the translation factors to the
ribosome, ultimately halting translocation along the mRNA template.229,233,235,236 A subset
of thiopeptides, including the thiomuracins and GE2270A, exert a separate mode of
antibacterial action by the inhibition of elongation factor Tu (EF-Tu). EF-Tu ordinarily
delivers aminoacylated tRNAs to the ribosome following translocation.49,228 When a
thiopeptide binds to EF-Tu, a portion of the recognition site for the aminoacyl tRNA
substrate is occluded and formation of an EF-Tu·aminoacyl-tRNA complex is
prevented.228,238,239
In addition to their well-known antibacterial properties, certain thiopeptides have
demonstrated antimalarial and anti-cancer activities. For both of these latter cases, it appears
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that the mode of action may be two-fold. Thiostrepton A inhibits two opposing aspects of
protein homeostasis in the malaria parasite Plasmodium falciparum: the proteasome and
protein synthesis within the parasite’s specialized apicoplast organelle.240–243 In cancer cell
lines, thiostrepton A appears to induce apoptosis through the interplay of proteasome
inhibition and direct interference with the forkhead box M1 (FOXM1) transcription
factor.244–246 Other activities ascribed to thiopeptides span a range that encompasses RNA
polymerase inhibition, renin inhibition, and some of these metabolites are proposed to serve
as streptomycete signal molecules.247–250 The challenges now remain to decipher which
aspects of the thiopeptide structure are key for each biological target, and then to apply that
knowledge toward the development of novel anti-infective and anti-cancer chemotherapies.
7.3 Biosynthesis of thiopeptides
At the time of this review’s preparation, ten thiopeptide biosynthetic gene clusters have been
identified.46–49,251–255 In addition to the precursor peptide (e.g. TpdA of the thiomuracin
cluster), at least six proteins, corresponding to TpdB–G, are found within each cluster. These
six proteins presumably provide the minimal set of post-translational modifications required
to construct the defining thiopeptide scaffold.49 The thiopeptides harbor structural features
similar to both lanthipeptides (Dha and Dhb residues) and the linear azol(in)e-containing
peptides (LAPs) and cyanobactins (thiazole structures).50,52 Not surprisingly, these
backbone modifications are installed by similar enzymes. Dehydration of Ser and Thr side
chains to introduce Dha and Dhb residues, respectively, is likely effected by one or two
proteins, TpdB and TpdC, each bearing weak similarity to the class I lanthipeptide LanB
dehydratases.90,91 Proteins similar to the cyclodehydratases (TpdG) and dehydrogenases
(TpdE) that construct the polyazoline rings of the cyanobactins and LAPs are predicted to
perform in a similar context for thiopeptide maturation.21,44,179 Cyclization of a linear
peptide is expected to provide the central pyridine/dehydropiperidine/piperidine of the
thiopeptides, and Bycroft and Gowland suggested this could ensue through a [4 + 2]
cycloaddition of two dehydroalanines (Fig. 13).223 Inactivation of tclM, a tpdD homolog, in
the thiocillin-producing Bacillus cereus strain led to the accumulation of a highly modified
and linear peptide that contains the two anticipated dehydroalanine resides.256 The
identification of this metabolite lends support to the Bycroft–Gowland proposal and
implicates a key role for TclM/TpdD and their homologs in this biochemically intriguing
transformation. At present, it remains to be determined whether this cycloaddition proceeds
in a concerted or stepwise process. The sixth protein found in all thiopeptide biosynthetic
systems, TpdF, does not display any significant similarity to proteins of known function, and
its biochemical role awaits elucidation. Like other RiPPs discussed in this review, the
biosynthetic machinery of thiopeptides is tolerant of many mutations in their linear substrate
peptides resulting in new variants.36,38,42,43 However, thiopeptides from the d and e series
may be unique among RiPPs in the manner by which the leader peptide is likely removed.
Rather than relying on proteolytic cleavage, the leader peptide is thought to be eliminated
from the central nitrogen-containing heterocycle (Fig. 13).50 Beyond the conserved six
proteins, one or more additional enzymes are embedded within each cluster to introduce the
specialized features of each metabolite, including hydroxylations, methylations, and
incorporation of an indolic or quinaldic acid macrocycle.46,49,255,257
7.4 Specific recommendations for the thiopeptide family
Given the overlap in nomenclature used between the LAP, cyanobactin, and lanthipeptide
modification enzymes and the current lack of a common naming scheme, a thiopeptide-
specific nomenclature for the core set of biosynthetic proteins seems appropriate. To be
consistent with the bulk of RiPP gene nomenclature, it is recommended that the precursor
peptide is annotated as “A”. It is also suggested that future annotations of thiopeptide gene
clusters follow the nomenclature outlined for the thiomuracins, wherein the precursor
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peptide and the core set of six genes were collinearly organized.49 By adopting this
nomenclature, proteins corresponding to the dehydratases will be designated as “B” and
“C”; the azoline-synthesizing dehydrogenase and cyclodehydratase are to be designated as
“E” and “G”, respectively; “D” is to be used for the protein implicated in the putative [4 + 2]
cycloaddition; and “F” should be assigned for the remaining conserved protein. Although
this annotation may lead to discontinuous name assignment for a cluster’s components, since
thiopeptide clusters do not all follow this gene organization, it will ultimately permit a
uniform notation for the core set of thiopeptide modification enzymes.
8 Bottromycins
The first member of a series of related compounds called bottromycins was originally
isolated from the fermentation broth of Streptomyces bottropensis DSM 40262,258 but their
structures were not definitively known until a total synthesis of bottromycin A2 in 2009 that
settled a series of structural revisions (Fig. 14).259 These compounds contain a number of
unique structural features including a macrocyclic amidine and a decarboxylated C-terminal
thiazole. In addition, like the proteusins (section 4), they contain a series of C-methylated
amino acids (Fig. 14). The bottromycins display potent antimicrobial activity against
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci
(VRE),260 and function by blocking aminoacyl-tRNA binding to the A-site of the bacterial
50S ribosome.261–263 Recently, using various genome mining and genome sequencing
methods, four studies reported that the bottromycins are RiPPs arising from an impressive
series of modifications.17–20 The biosynthetic gene clusters were obtained by shot-gun
sequencing of the genomes for Streptomyces sp. BC1601917 and S. bottropensis18,19 that
both were known to produce bottromycin A2, B2, and C2 (Fig. 14).264–267 In an alternative
strategy, a search of the non-redundant databases for a sequence encoding a putative linear
core peptide GPVVVFDC provided a hit in the sequenced genome of the plant pathogen
Streptomyces scabies 87.22, which was subsequently shown to produce bottromycins A2,
B2, and C2.18,19 And in a final approach, a new analog, bottromycin D (Fig. 14) was
detected in a metabolomics study of the marine ascidian-derived Streptomyces sp.
WMMB272; subsequent genome sequencing revealed its biosynthetic gene cluster.20
8.1 Biosynthesis of the bottromycins
All four studies report the intriguing observation that the precursor peptide to the
bottromycins does not contain an N-terminal leader peptide, but instead a C-terminal
extension of 35–37 amino acids (Fig. 15). The exact role of this extension is at present
unclear, but it likely guides the biosynthetic enzymes. It is significantly larger than the C-
terminal recognition sequences used for N-to-C cyclization in cyanobactins (section 6),
amatoxins (section 14), cyclotides (section 15), and orbitides (section 16), and because it
likely functions in a role more similar to the leader peptides, the term follower peptide was
introduced.19 Bioinformatics analysis has been used to predict the function of some of the
genes that are found in the gene clusters of all four strains, which are highly similar in
organization and sequence.17–20 Three putative cobalamin-dependent class B162 radical-
SAM methyltransferases were predicted to catalyze the methylation at the non-nucleophilic
β-carbons. The Cys constellation in these enzymes (CxxxxxxxCxxC)18 is different from the
canonical CxxxCxxC motif involved in Fe-S clusters in most radical-SAM proteins, but is
also found in the polytheonamide C-methyltransferases PoyB and PoyC (section 4). The
predicted function of these radical-SAM methyltransferases has been experimentally
validated by gene deletion experiments in a heterologous expression system using
Streptomyces coelicolor A3(2),17 and by gene deletions in S. scabies.18 One of the enzymes
is responsible for C-methylation of the Pro residue as its deletion resulted in the exclusive
production of bottromycin B2.17,18 Similarly, a second radical-SAM methyltransferase is
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specific for the C-methylation of the Phe residue as its disruption resulted in the production
of a new metabolite, bottromycin D2.17 Deletion of the third methyltransferase resulted in
the production of a compound that lacked two methyl groups,17,18 which was identified by
tandem MS as bottromycin E2 (Fig. 14).17 Hence, this third methyltransferase adds methyl
groups to two of the three original Val residues of the precursor peptide (Fig. 15). In
addition to the radical-SAM methyl-transferases, the gene clusters also contain an O-methyl-
transferase that was shown to be responsible for the methylation of the Asp residue (Fig.
15).17
The gene clusters also contain two genes with a YcaO-like domain similar to the D-protein
involved in LAP biosynthesis (section 5). This domain was shown for LAPs to use ATP to
phosphorylate the amide backbone during the cyclodehydration reaction,173 and hence at
least one of the two YcaO-like genes is predicted to be involved in thiazoline
formation.17–20 Interestingly, the bottromycin gene cluster does not contain the C-protein
that together with the D-protein promotes efficient cyclodehydration in LAPs (section 5) or
cyanobactins (in which the C and D proteins are fused in one protein, see section 6). Why
two YcaO-domain containing proteins are encoded in the bottromycin gene cluster is at
present unclear, but one possibility is that one is involved in cyclodehydration to form a
thiazoline and the second in the macrocyclodehydration to form the amidine structure (Fig.
15).17–19
Two genes encoding putative proteases/hydrolases and one gene encoding a putative
aminopeptidase may be involved in removal of the follower peptide and the N-terminal Met,
and possibly to aid formation of the unique macrocyclic amidine. Finally, a gene encoding a
cytochrome P450 has been suggested to facilitate the oxidative decarboxylation of the C-
terminal residue by hydroxylating the β-carbon of the Cys.19 The observed epimerization at
the Asp α-carbon may possibly occur non-enzymatically as a consequence of its location
next to a thiazole/thiazoline as has also been suggested for cyanobactins (section 6).32,205
The order of this impressive array of posttranslational modifications is currently not known
and one possibility out of many is shown in Fig. 15. A putative bottromycin-transporter was
also identified in the biosynthetic gene cluster,17–20 and proposed to be involved in the
export of and self-resistance to bottromycins. This hypothesis was verified by an
overexpression experiment with the Streptomyces coelicolor A3(2) heterologous expression
system, which led to a 20 fold increase of bot-tromycin production yields compared to a
parallel experiment using the unmodified pathway.17
8.2 Specific recommendations for the bottromycin family
It is recommended to use the term follower sequence for the unique C-terminal extension
found in the bottromycin precursor peptides. Since four independent studies all used
different gene annotations, at present a common gene nomenclature is not in use. In line
with the recommendations for most other RiPPs, the use of the designation A is
recommended for the gene encoding the precursor peptide in biosynthetic gene clusters that
are uncovered in future studies.
9 Microcins
Historically, the name microcins has been used for ribosomally synthesized antimicrobial
peptides from Enterobacteriaceae, mainly Escherichia coli. In addition to their lower
molecular masses (<10 kDa), microcins differentiate from colicins, the larger antibacterial
proteins (30–80 kDa) produced by Gram-negative bacteria, by a resistance to proteases,
extreme pH and temperature, and in many cases the presence of post-translational
modifications. Fourteen representatives have been identified thus far (for reviews
Arnison et al. Page 15
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
see12,268,269) and eight of them have been isolated and structurally characterized (e.g. Fig.
16).
Most microcins are plasmid-encoded peptides. Their biosynthetic clusters display a
conserved general organization, with (i) a structural gene encoding the precursor peptide, (ii)
a self-immunity gene that protects the producing strain against its own toxic peptide, (iii)
genes encoding the microcin export system, and (iv) often several genes encoding auxiliary
proteins or modification enzymes. The classification of microcins adopted presently
distinguishes two classes.12,270 Class I consists of three plasmid-encoded peptides with a
molecular mass below 5 kDa that have extensive backbone post-translational modifications:
microcins B17, C (also called C7, C51 or C7/C51), and J25. Two of these compounds,
microcins B17 and J25 were initially believed to be unique to Enterobacteria, but the
genome sequencing efforts have demonstrated that they are part of larger families of
structurally related peptides that are produced by a variety of bacteria. As described in the
section on the LAP family, microcin B17 is a 43 amino acid peptide that carries four
thiazole and four oxazole heterocycles (Fig. 9), which result from the modification of six
glycines, four serines and four cysteines in the core peptide of the 69 amino acids long
microcin precursor peptide (Fig. 8).271 Microcin C is an N-for-mylated heptapeptide
covalently linked to adenosine mono-phosphate via its C-terminal aspartate through an N-
acyl phosphoramidate linkage;272 the phosphate group is further esterified with 1,3-
propanolamine (Fig. 16A). Microcin J25 is a 21-amino acid lasso peptide.273 It consists of a
macrolactam, which is formed by the N-terminal amino group and the side-chain
carboxylate of an aspartate at position 8, through which the peptide tail is threaded and
firmly trapped by steric interactions, thus forming a lasso. Therefore, microcin J25 belongs
to both families of microcins from Enterobacteria and lasso peptides, which are mainly
synthesized by Actinobacteria (section 10).273–275
Class II microcins consist of higher molecular mass peptides in the 5–10 kDa range. This
class is further subdivided into two subclasses, IIa and IIb. Class IIa comprises three
plasmid-encoded peptides, microcins L, V and N (also named microcin 24) that are not post-
translationally modified and that will not be considered here. Class IIb consists of
chromosome-encoded linear microcins that carry a C-terminal siderophore (Fig. 16B).276,277
9.1 Biological activities of microcins
Microcins display potent antibacterial activity against Gram-negative bacteria, and
specifically Enterobacteria. They exhibit diverse mechanisms of antibacterial activity and
appear attractive models for the design of novel bioactive peptides with anti-infective
properties.12,269,278 Microcins have receptor-mediated mechanisms of antibacterial activity
that improve their uptake in sensitive bacteria. Therefore, they have a narrow spectrum of
activity and minimal inhibitory concentrations in the nanomolar range. Microcins hijack
receptors involved in the uptake of essential nutrients, and many parasitize iron side-rophore
receptors or porins. Those using siderophore receptors are also dependent on the TonB-
ExbB-ExbD inner-membrane protein complex, which ensures energy transduction to the
outer membrane and its receptors, using the proton-motive force from the cytoplasmic
membrane. Microcin J25 uses the receptor to ferrichrome (FhuA), microcins B17 and C use
the porin OmpF, and microcins E492 and M use the receptors to catechol siderophores
(FepA, Cir and Fiu). After crossing the outer membrane, microcins often require an inner
membrane protein to exert their toxic activity, such as SbmA for microcins B17 and J25 or
components of the mannose permease for microcin E492. Others require an ABC-
transporter, such as YejABEF for microcin C. Many microcins inhibit vital bacterial
enzymes, such as DNA gyrase (microcin B17) or RNA polymerase (microcin J25). The
latter blocks transcription by binding in the secondary channel that directs NTP substrates
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toward the RNA polymerase active site, resulting in its obstruction in a cork-in-the-bottle
fashion.
A two-step processing procedure inside target bacteria is required to activate microcin C.
First peptide deformylase removes the N-terminal formyl group, and then several broad-
specificity aminopeptidases target the ultimate peptide bond Ala6-Asp7 and cleave off the
N-terminal peptide (Fig. 16A). The resulting molecule is a mimic of aspartyl adenylate,
which inhibits aspartyl tRNA synthetase and therefore blocks protein synthesis at the
translation step. To exert its bactericidal activity, the class IIb microcin E492 forms channels
in the inner membrane.
With the exception of the lasso structure of microcin J25 (see section 10), three-dimensional
structures of microcins are not available.273,279–281 However, in the absence of precise
three-dimensional structures, structure–activity relationships of class I microcins have been
undertaken. A chemical strategy was developed to prepare a series of microcin C analogs,
which retained the Trojan horse mechanism of antibacterial activity of the natural microcin,
while targeting different aminoacyl-tRNA synthetases specified by the last amino acid that
is linked to the adenosine.282 In the case of microcin B17, point mutations indicate that the
number and position of the thiazole and oxazole rings in the microcin structure are essential,
and that the C-terminal bis-heterocycle is critical.51
9.2 Microcin biosynthesis
All microcins except microcin C, which does not possess a leader peptide and is secreted
without cleavage of a precursor, are translated from their respective mRNA as precursor
peptides consisting of an N-terminal leader peptide and a C-terminal core peptide, which
undergoes post-translational modifications prior to becoming the mature active microcin.12
Class II microcins result from maturation of large precursors carrying small conserved
leader peptides (15–19 amino acids). Class I microcins have longer leaders of 19–37 amino
acids that (at present) do not display common features, neither in length nor in amino acid
sequences. Removal of the microcin leader peptides most often occurs at a specific cleavage
site, the typical double-glycine motif or the glycine-alanine motif found in proteins exported
through ABC (ATP-binding cassette) transporters.283 The roles of the leader peptides have
not been fully clarified to date, but they could contribute to maturation, secretion, protection
of the precursor against degradation, or to keeping the precursor inactive inside the host cells
during biosynthesis.16
The biosyntheses of microcin B17 and J25 have been reconstituted in vitro.51,284,285 Mature
microcin B17 was obtained from the precursor McbA in the presence of the modification
enzymes McbB, McbC, and McbD that form the microcin B17 synthetase complex.51 We
note that the original gene designations for the microcin B17 gene cluster were
alphabetical,286 and were different from that recommended in section 5 for LAPs. In this
early designation McbB corresponds to the “C” protein of LAPs and McbC was the flavin
dependent dehydrogenase (designated B in other LAPs).51,52 The oxazole and thiazole
heterocycles result from a series of cyclization, dehydration, and dehydrogenation reactions
as described in section 5. During the modification process, the McbBCD complex
recognizes the leader peptide that has a helical structure.58 Upon removal of the N-terminal
26-amino acid leader peptide, presumably by TldD/TldE,287 mature microcin B17 is
exported from the cell by the dedicated ABC transporter McbEF.
The maturation process of microcin C requires five steps including three modifications of
the precursor MccA and two cleavage steps that are accomplished in the target cells:278,288
(i) conversion of Asn7 to a derivatized isoAsn7, (ii) formation of an N-P bond between the
amide group of isoAsn7 and the α-phosphate of ATP catalyzed by MccB, affording the
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peptidyl-AMP linkage, (iii) aminopropylation of the phosphoramidate using two enzymes
encoded by mccD and mccE, (iv) deformylation, and (v) proteolysis at the Ala6–Asp7
peptide bond (see section 9.1).
The modification anchored at the C-terminus of microcin E492 is a C-glucosylated linear
trimer of 2,3-dihydroxybenzoyl-L-serine (DHBS), which itself results from linearization of
the cyclic catechol-type siderophore enterobactin.289–291 Enterobactin and salmochelin, its
glycosylated counterpart, are first made by nonribosomal peptide synthetases. Modification
of the 84-amino acid ribosomally produced peptide at its C-terminal serine with the
sidereophore requires four genes mceCDIJ. MceC and MceD ensure enterobactin
glucosylation and linearization, while MceI and MceJ are responsible for the formation of
the ester linkage between the glucosylated enterobactin and the C-terminal serine of the
microcin (Fig. 16B). The biosynthesis of the lasso peptide microcin J25 is discussed in
section 10.2.
9.3 Specific recommendations for the microcin family
At present, the precursor peptide and common biosynthetic genes encoding proteins
involved in export, immunity and modification enzymes are not always given the same gene
name (e.g. mcxA for the precursor peptides to the microcins). Given the relatively small
number of microcins, we recommend that a common designation of biosynthetic genes will
be systematically implemented, including using the nomenclature systems implemented for
other RiPPs, such as LAPs and lasso peptides.
10 Lasso peptides
Lasso peptides form a growing class of bioactive bacterial peptides that are characterized by
a specific knotted structure, the lasso fold.292 The producing bacteria are most often Acti-
nobacteria (Streptomyces, Rhodococcus), but some are Proteobacteria (Escherichia,
Burkholderia).273–275 They consist of 16–21 residues, with an N-terminal macrolactam,
resulting from the condensation of the N-terminal amino group with a side-chain
carboxylate of a glutamate or aspartate at position 8 or 9. Lactam formation irreversibly
traps the C-terminal tail within the macrocycle. The net result is a highly compact and stable
structure that to date has proven inaccessible by peptide synthesis. Lasso peptides are
remarkably resistant to proteases and denaturing agents, and this high stability and their
biological activities have attracted much interest. Indeed, the known lasso peptides inhibit
enzymes or antagonize receptors, which confer antimicrobial properties on some of them.273
Furthermore, the lasso structure has recently been shown to be an efficient scaffold for
epitope grafting,40 demonstrating the capacity to give novel biological functions to the lasso
fold.
Lasso peptides are classified into three classes (Fig. 17A). Members of the first class contain
two disulfide bonds and the first residue is a cysteine. This class contains four
representatives: siamycin I (also called MS-271),293,294 siamycin II and RP-71955,295,296
and SSV-2083.6 Class II lasso peptides do not contain disulfides and the first residue is a
glycine. This class contains eight representatives: RES-701,297–300 propeptin,301,302
anantin,303,304 lariatins A and B,305 microcin J25,306,307 capistruin,308,309 and
SRO15-2005.6 The third class, which was recently discovered and encompasses a single
peptide, BI-32169,310 is characterised by the presence of a single disulfide bond and a
glycine at the N-terminus. In all of the lasso peptides identified to date, the residue providing
the side-chain carboxylate implicated in the macrolactam is a Glu at position 8 or an Asp at
position 9 (or position 8 in one example), pointing to a stringent role of the size of the
macrolactam in maintaining the lasso fold. A recent genome mining study has identified 76
potential lasso peptide producers spanning nine bacterial phyla and an archaeal phylum.311
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One gene cluster from the freshwater bacterium Asticcacaulis excentricus was
heterologously expressed in E. coli leading to the production of the largest lasso peptide to
date, astexin-1.311 It consists of 23 amino acids and unlike most other lasso peptides is
highly polar.
Microcin J25 produced by E. coli AY25 is the archetype of lasso peptides and the most
extensively studied. Its lasso structure of type II results from linkage of the amino group of
Gly1 to the side-chain carboxylate of Glu8 to give the N-terminal macrolactam; the threaded
13-residue C-terminal tail (Fig. 17A) is maintained irreversibly in the ring by the bulky side-
chains of two aromatic residues, Phe19 and Tyr20, that straddle the ring and prevent the tail
from escaping. Its three-dimensional structure contains two small anti-parallel β-
sheets.279–281 One involves residues 6–7 located in the ring and residues 18–19 of the
threading C-terminal tail. The other is located in the loop region of the lasso structure and
comprises residues 10–11 and 15–16 that form a hairpin-like structure including a β-turn
that involves residues 11–14 (Fig. 17B).
Capistruin is a 19-residue peptide that is produced by Burkholderia thailandensis E264 and
contains a 9-residue ring resulting from a Gly1-Asp9 isopeptide bond.308 Six amino acids
out of the 10-residue C-terminal segment pass through the ring, forming quite a long tail,
which is trapped in the ring by the side-chains of Arg11 and Arg15. Similar to microcin J25,
its three-dimensional structure contains a small antiparallel β-sheet involving residues 7–8 of
the ring and residues 13–14 of the threading C-terminal tail that are connected by a β-turn
involving residues 9–12. Having a shorter and tighter loop, capistruin lacks the second β-
sheet present in the loop region of microcin J25.
10.1 Biological activities of lasso peptides
Lasso peptides are usually enzyme inhibitors or receptor antagonists. These properties
confer some of them with antibacterial activity, which is directed against either Gram-
negative bacteria or Gram-positive bacteria. The spectrum of activity is generally limited to
bacteria phylogenetically related to the producing bacteria, helping them to colonize a given
biotope. In class I, siamycin I (MS-271) is an inhibitor of the myosin light chain kinase and
an anti-HIV agent,293,294 and siamycin II and RP-71955 are anti-HIV agents.293,294 In the
class II lasso peptides, RES-701 peptides are antagonists of the type B receptor of
endothelins,297–300 propeptin is a prolyl endopeptidase inhibitor,301,302 anantin is an
antagonist of the atrial natriuretic factor,303,304 lariatins A and B are anti-mycobacterial
agents,305 and microcins J25306,307 and capistruin308,309 are RNA polymerase inhibitors and
antibacterial agents. The single class III lasso peptide BI-32169 is an antagonist of the
glucagon receptor.310
10.2 Lasso peptide biosynthesis
Microcin J25 and capistruin are the two lasso peptides that have been the most extensively
studied with regards to their biosynthetic pathways. Both microcin J25 and capistruin arise
from four-gene clusters (mcjABCD and capABCD) in E. coli and B. thailandensis,
respectively. Microcin J25 has been the model for the study of the biosynthesis of lasso
peptides. Its production requires McjB and McjC to control the acquisition of the lasso fold
from the 58-amino acid linear precursor.284 On the basis of sequence comparisons,269,284
McjB is believed to be an ATP-dependent cysteine protease that cleaves off the leader
peptide. McjC has homology with Asn synthetase B,284,285 and is hypothesized to form the
isopeptide bond between the glycine at position 1 generated upon proteolytic cleavage of the
leader and the Glu8 side-chain carboxylate, which is activated through an acyl-AMP
intermediate. McjB and McjC are two interdependent enzymes that mutually need the
physical presence of their partner to carry out their enzymatic reactions. The distinct
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functions of McjB and McjC were recently demonstrated by in vivo mutagenesis studies of
putative active site residues,312 and in vitro studies using recombinant precursor and
maturation enzymes.313 McjC was confirmed to be a lactam synthetase and McjB was
shown to be a novel cysteine protease that requires ATP hydrolysis for proteolytic
activity.313 In view of the pre-folding step required for obtaining the lasso fold, the ATP-
dependent character of McjB could be related to a chaperone function. Interestingly, only
the N-terminal eight residues of the leader peptide are required for recognition of the
precursor McjA by the maturation machinery.68 In particular, the Thr residue in the
penultimate position of the leader peptide is proposed to be a recognition element for the
maturation enzymes.314 The final product is believed to be transported from the cytoplasm
by an ABC transporter.284,315 In contrast to microcin J25 and capistruin, which are encoded
by four-gene clusters, lariatins A and B, produced by Rhodococcus jostii, result from a five-
gene cluster (larABCDE).316 It is proposed that processing of the precursor LarA by LarB,
LarC and LarD leads to the mature lasso peptide, which is then exported by LarF.316 Taking
into account the sequence similarities between the larB and larD gene products and the
modification enzymes identified for microcin J25 and capistruin, it is suggested that LarC,
the function of which remains unclear, is a third enzyme essential for lariatin biosynthesis
that would be specific to Gram-positive bacteria.
Two systematic structure–activity relationship studies of microcin J25 have been performed,
paving the way for future studies deciphering the roles of specific amino acids in the lasso
structure and antibacterial activity.31,39 The most striking conclusion of these studies was
that production and activity of the lasso peptide were tolerant to amino acid substitutions at
most of the positions in the 21 amino acid core sequence. Another recent study demonstrated
that the C-terminal residue, the bulky residue below the ring, and the size of the ring are
critical for generating the lasso structure.317 Interestingly, some amino acid substitutions
afforded branched-cyclic peptides instead of lasso peptides that were devoid of antibacterial
activity. Moreover, the tail portion below the ring and the C-terminal glycine appeared
critical for the antibacterial activity but could be modified without affecting lasso formation.
Using a heterologous capistruin production system in E. coli, a series of mutants of the
precursor protein CapA have been generated, showing that only four residues of the lasso
sequence are critical for maturation of the linear precursor into the mature lasso structure.41
Thus, the biosynthetic machineries of both microcin J25 and capistruin systems have low
substrate specificity, which is a promising feature towards lasso peptide engineering.
10.3 Specific recommendations for the lasso peptide family
Similar to microcins, a common gene nomenclature should be adopted for lasso peptides in
which the precursor and common biosynthetic genes are always given the same gene name:
“A” for the genes encoding the precursor peptides, “B” for genes encoding the
transglutaminase/cysteine protease homologs, “C” for genes coding for the Asn synthetase
homologs, and “D” for genes encoding ABC transporters.
11 Microviridins
Microviridins represent a family of cyclic N-acetylated trideca and tetradecapeptides that
contain intramolecular ω-ester and/or ω-amide bonds. Like the lasso peptides, most
microviridins contain lactams, but unlike the lasso peptides, these structures are not formed
from the N-terminal amine but rather between ω-carboxy groups of glutamate or aspartate
and the ε-amino group of lysine.318 Furthermore, microviridins also contain lactones
generated by esterification of the ω-carboxy groups of glutamate or aspartate with the
hydroxyl groups of serine and threonine. Lactone and lactam formation results in an
unparalleled tricyclic architecture (Fig. 18). The crosslinking amino acids are part of a
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conserved TXKXPSDX(E/D)(D/E) central motif, whereas the N- and the C-termini of
microviridin core peptides are highly variable.319 The related bicyclic dodecapeptide
marinostatin (Fig. 18) contains only ω-ester bonds and a slightly altered microviridin-type
central motif (TXRXPSDXDE).320
Microviridins have so far only been detected in bloom-forming freshwater cyanobacteria of
the genera Microcystis and Planktothrix. The prototype of the family, microviridin A, was
described for Microcystis viridis strain NIES 102 in 1990.318 Eleven further structures of
related cyanobacterial metabolites, microviridin B–L, were elucidated in the past twenty
years from laboratory strains and field samples.321–324 Bioinformatic analysis of complete
microbial genomes, however, suggests a more widespread potential for microviridin
biosynthesis than expected. Putative microviridin precursor genes were detected in a large
number of cyanobacterial genomes, including strains of Cyanothece, Anabaena, Nodularia
and Nostoc.323 In addition, the presence of related microviridin-type gene clusters in
genomes of the sphingobacterium Microscilla marina ATCC 23134 and the myxobacterium
Sorangium cellulosum Soce56 suggests an occurrence of microviridins beyond the
cyanobacterial phylum,323 and the related bicyclic peptide marinostatin has been detected in
the marine proteobacterial strain Alteromonas sp. B-10-31.320
11.1 Biological activities of microviridins
Microviridins were initially discovered through a bioactivity-guided screening program for
inhibitors of serine type proteases in cyanobacteria.318 The different variants show distinct
protease inhibition profiles with specificities for elastase, trypsin or
chymotrypsin,321,322,324,326 and activities in the low nanomolar range.322,326 For example,
microviridin B (Fig. 18) specifically inhibits elastase and has potential in the treatment of
lung emphysema,322 and microviridin J inhibits a trypsin-type enzyme from Daphnia and
disrupts the molting process of the animals.326 Microviridins may therefore play an
important role in the trophic networks of freshwater lakes. Similarily, the bicyclic
marinostatin (Fig. 18) has inhibitory activity against the protease subtilisin.320
11.2 Biosynthesis of microviridins
Microviridin biosynthesis has been partially characterized in vivo and in vitro for the two
cyanobacterial genera Microcystis and Planktothrix.323,327 The corresponding gene clusters
have been designated mdnA–E and mvdA–E, respectively.323,327 The precursor peptides
MdnA and MvdE contain a strictly conserved PFFARFL motif in their leader peptide that is
essential for post-translational modification reactions.319 The lactone and lactam structures
are introduced by two novel types of ATP grasp ligases, MdnC and MdnB, and MvdD and
MvdC, respectively.323,327 The four enzymes show close similarity to each other and belong
to the RimK family of enzymes that catalyze cross-links of carboxyl groups with amine or
thiol groups.328 In vitro characterization revealed the activity of MvdD as the ω-ester ligase
and MvdC as the ω-amide ligase.323 Further analysis of MvdD and mutational studies of the
precursor peptide MvdE in Planktothrix suggested a strict order for the formation of the
crosslinks, with the larger lactone forming first and the smaller lactone forming second.329
The size of both rings appears to be inflexible.329 Lactonization is then followed by lactam
formation via MvdC.323 The cluster further encodes a GNAT-type N-acetyl transferase,
designated MdnD and MvdB in Microcystis and Planktothrix, respectively.323,327 MvdB
catalyzes the N-acetylation of the N-terminal amino acid of the lactonized and lactamized
premature peptide.323 The microviridin gene cluster does not encode a protein with protease
signatures that could be responsible for the cleavage of the leader peptide. However, the
associated ABC transporter MdnE is crucial for correct processing in vivo and may play a
scaffolding role thereby guaranteeing correct processing.319 Interestingly, the putative gene
cluster in Anabaena PCC7120 encodes a precursor peptide that contains multiple putative
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core peptides,327 similarly to the multiple RiPPs generated from a single peptide that has
been found for cyanobactins and cyclotides (sections 6 and 15).
11.3 Specific recommendations for the microviridin family
The characteristic lactone and lactam structures are the signature motifs that define this
group. Moreover, the three peptide modifying enzymes do not show close similarity to
enzymes of other PRPS classes. The two enzymes catalyzing macrocyclization, MdnC/
MvdD and MdnB/MvdC, can thus be taken as enzymatic basis for the classification of the
microviridin group of peptides. Marinostatin and the corresponding biosynthesis gene
cluster do not meet all criteria. However, as the two lactones and the ATP grasp ligase
encoded by the marinostatin gene cluster resemble characteristic features of the microviridin
class, marinostatins should be considered as a specific subgroup of microviridins. Two
different gene nomenclatures (mdn, mvd) have been assigned to the related gene clusters in
the two cyanobacterial genera.323,327 As both in vivo and in vitro characterization provided
important insights into microviridin biosynthesis, standardization of this historical
nomenclature is not possible without omitting important results. Future investigations into
microviridins, however, should follow at least one of the existing gene designations.
12 Sactipeptides: peptides with cysteine sulfur to α-carbon crosslinks
This section focuses on a small but growing class of ribosomally synthesized peptides that
have undergone post-translational modification to introduce intramolecular linkages
between cysteine sulfur and the α-carbon of another residue. Although some
diketopiperazines (cyclodimers of amino acids) such as gliotoxin and aranotin have long
been known to have sulfur to α-carbon linkages,330 those compounds are made by non-
ribosomal peptide synthetase systems. At least for the case of gliotoxin, the sulfur is
introduced by nucleophilic attack of glutathione on a diketopiperazine N-acyl imine.331 The
first report of a ribosomally-made peptide with a sulfur to α-carbon linkage was the
structural elucidation in 2003 of subtilosin A.332 In the meantime at least six such structures
have been reported from Bacillus species. These include a naturally occurring hemolytic
subtilosin A mutant (T6I)333 from B. subtilis, the anti-clostridial Trn-α and Trn-β from B.
thuringiensis (together forming the two-component system thuricin CD),334 thurincin H
from another strain of B. thuringiensis,335 and the cannibalistic sporulation killing factor
(SKF) from B. subtilis (Fig. 19).336 The term sactibiotic (sulfur to alpha-carbon antibiotic)
has been suggested to describe peptides in this group.337 The more general term sactipeptide
may be appropriate as some compounds with such a structural feature but lacking
antimicrobial activity may be discovered in the future. The sulfur to α-carbon linkage is also
found in cyclothiazomycin, a thiopeptide from Streptomyces hygroscopicus that has a C-
terminal cysteine sulfur to α-carbon link with an alanine.338–340
All sactipeptides are relatively hydrophobic, and in the cases examined by NMR
spectroscopy, have a 3D solution structure that resembles a hairpin with hydrophobic
residues pointing to the exterior (Fig. 20). These include subtilosin A,332,341 Trn-α and Trn-
β,342 and thurincin H.335 In subtilosin A and its T6I variant,333 as well as in SKF,336 the C-
and N-termini at the ends of the hairpin are cyclized to form an amide bond. Both circular
and open hairpin structures are conformationally restricted by the crosslinks of cysteine
sulfur to the α-carbon of residues on the opposite side of the structure (Fig. 20). This
unusual linkage is relatively stable under acidic conditions, but treatment with base and
reducing agent rapidly cleaves it to form a free cysteine and a reactive N-acyl imine
intermediate341 that can tautomerize to a more stable enamine form. An analogous process
resulting in a related thiol elimination product occurs during mass spectrometric analysis,
and can thereby give the initial impression that the cysteine residues are not modified and
that the residues originally linked at the α-carbon are dehydroamino acids.334–336
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Most of the compounds isolated thus far having this modification show some antimicrobial
activity, but the detailed mechanisms are not well understood. The high potency, and in
some cases narrow specificity (e.g. Trn-α and Trn-β),343 of antimicrobial action suggests
that many of these molecules require recognition of a receptor molecule in the cell
membrane of target organisms. Thus far only the interaction of subtilosin A with lipid
bilayers has been examined in detail.344,345 Subtilosin A adopts a partially buried orientation
in such lipid bilayers. Interestingly, subtilosin A shows spermicidal activity although it is not
haemolytic at low concentrations.346 However, replacement of its threonine-6 with
isoleucine gives a variant that is potently haemolytic.333 As expected for a bacteriocin
produced by a Gram-positive organism (B. subtilis), subtilosin A displays good activity
against other Gram-positive species. Surprisingly, this effect is inhibited by EDTA through
an unknown mechanism.347 However, at high concentrations in the presence of EDTA,
subtilosin A can penetrate the outer membrane of some Gram-negative species to exert an
antimicrobial effect.
The key sulfur to α-carbon crosslinks in subtilosin were proposed to be generated by a
single radical S-adenosylme-thionine (SAM) enzyme AlbA,348 a hypothesis that was
recently confirmed by in vitro reconstitution of enzyme activity.349 AlbA was shown to
sequentially install the crosslinks of all three cysteines with one threonine and two
phenylalanine residues on the linear subtilosin precursor still bearing the leader peptide.349
The presence of the leader was essential for activity, and the enzyme distinguished between
different residues to which the cysteine is coupled. Similarly, a single gene for a radical
SAM enzyme is present in the cluster that is proposed to be responsible for generating all
four crosslinks in thurincin H,350 and two such genes are found in the thuricin CD cluster,
presumably one for crosslinking Trn-α and the other for modifying Trn-β.334 The
requirement for such radical SAM enzymes has recently been used for genome mining to
identify other possible peptides that may have analogous modifications.4,5 In addition to
their involvement in sactipeptide biosynthesis, radical SAM proteins are also found near
peptides that do not contain Cys and that therefore cannot make thio-ether linkages between
Cys sulfurs and alpha carbons. Examples are found in the proteusins and PQQ biosynthetic
pathways (sections 4 and 20). Hence, the presence of radical-SAM proteins must be
evaluated in the context of the entire gene cluster and/or structure elucidation of the
resulting RiPP before functional roles can be assigned.
12.1 Specific recommendations for sulfur to α-carbon linked peptides
To broaden the scope with respect to possible future biological activities that may be
discovered, these compounds should be called sactipeptides rather than sactibiotics. A
common gene nomenclature should be adopted for this group, at least for those cases where
the genes are homologous. This nomenclature should be based on the thuricin CD genes,334
using the designation “A” for the precursor peptide, “C” and “D” for the radical-SAM
protein(s), and “F” and “G” for ABC-transporters. The designation “P” should be used for
currently unidentified proteases that may be encoded in biosynthetic gene clusters that await
discovery.
13 Bacterial head-to-tail cyclized peptides
Although many peptides are intramolecularly cyclized via amide bonds, this section focuses
exclusively on relatively large bacterial peptides (35–70 residues) that are ribosomally
synthesized and have a peptide bond between the C and N termini. As discussed below,
these peptides are distinguished from other head-to-tail cyclized peptides discussed in this
review (cyanobactins, amatoxins, orbitides, and cyclotides) by both their size and the
biosynthetic machinery that achieves macrocyclization. The most well-studied and famous
of these is enterocin AS-48, a potent antimicrobial agent isolated from Enterococcus,351 but
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over the last decade at least nine others have been purified and characterized (Fig. 21).200
All are bacteriocins from Gram-positive organisms. They include: butyrivibriocin AR10
(BviA),352 gassericin A (reutericin 6) (GaaA),353,354 circularin A (CirA),355 subtilosin A
(SboA),332,341,348,356 uberolysin (UblA),357 carnocyclin A (CclA),358,359 lactocyclicin Q
(LycQ),360 leucocyclicin Q (LcyQ),361 garvicin ML (GarML)362 and the cannibalistic
sporulation killing factor (SKF) of Bacillus subtilis.336 Recent reviews have appeared on the
structures, properties and genetics of production of this group,55,200 and more specifically,
on enterocin AS-48.351
Although most of these peptides show little sequence homology, they tend to be resistant to
high temperature (100 °C) treatment, to cleavage by many proteases, and to alterations in
pH. They are usually quite hydrophobic and appear to exert their antimicrobial activity by
targeting the cell membranes of other bacteria to create pores and cause ion permeability
with consequent cell death. They have been classified into three groups.200,359 Type i are the
AS-48 like peptides that also includes uberolysin, circularin A, lactocyclicin Q, and
carnocyclin A. These peptides tend to be cationic at physiological pH and have relatively
high isoelectric points (pI > 9). Type ii are the gas-sericin like peptides that includes
butyrivibriocin AR10. These are anionic or neutral at physiological pH and have lower
isoelectric points. Subtilosin A (35 residues) and its variants333 comprise an unrelated group
that are not only much smaller, but also have three sactipeptide crosslinks as discussed in the
previous section. The SKF peptide is also small (26 residues), has one sactipeptide link and
one disulfide bridging the ring and is more closely related to subtilosin A than the larger
circular peptides.336 The genetic determinants of a number of circular bacteriocins have
been reported, and they can be located either on the chromosome or on plasmids. The
structural genes all encode N-terminal leader peptides that are cleaved during maturation,
but the length of these can vary from 2 residues (lactocyclicin Q) to 35 residues (AS-48). A
significant number of other genes (up to 10 genes including the structural bacteriocin gene)
are often necessary to obtain full production of the cyclic antimicrobial peptide. Many of
these are predicted to code for membrane-bound proteins of uncertain function.
The three dimensional structures of enterocin AS-48 (X-ray crystallography),363 carnocyclin
A (NMR spectroscopy),359 and subtilosin A (NMR spectroscopy)332,341 have been reported.
Despite low sequence similarity, the three dimensional structures of the large bacteriocins
AS-48 (70 residues) and carnocyclin A (60 residues) are remarkably similar and have a
saposin fold of 5 and 4 α-helices, respectively (Fig. 22). Structural predictions based on the
sequences of the other large type i and type ii cyclic bacteriocins suggests that they too may
have saposin fold arrangements with four-helix bundles capped by either another α-helix as
in AS-48 or with a less structured loop that replaces it for the shorter peptides of 60
residues.359 Despite similarities in three dimensional structures, the biological functions of
these circular peptides appear to be quite different. For example, carnocyclin A is
monomeric and shows anion binding and membrane transport properties.364 In contrast,
AS-48 is dimeric and the dynamic reorganization of the interface between the two units is
believed to play a key role in membrane pore formation.363 Subtilosin A is much smaller (35
residues) and has a quite different structure that does not belong to the saposin fold (see
section 12).332,341 For all of these cyclic peptides, the N-to-C cyclizations appear to rigidify
the structures in such a way that a significant number of hydrophobic residues are displayed
to the outside, which is presumably important for their antimicrobial function. However, the
detailed mechanisms of action of most of these head-to-tail cyclized peptides are not known.
13.1 Biosynthesis of bacterial head-to-tail cyclized peptides
In terms of biosynthesis, the structural genes for these peptides indicate formation of a
precursor with an N-terminal leader sequence that can vary greatly in length. The N-terminal
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leaders for leucocyclicin Q and lactocyclicin Q consist of only two residues.360,361
Circularin A and uberolysin are initially made with N-terminal leaders of three and six
residues, respectively.355,357 In contrast, enterocin AS-48 has a 35 residue leader.351 In all
cases discovered thus far, the structural gene shows no additional residues at the C-terminus,
unlike the precursors for cyanobactins, amatoxins, cyclotides, and most orbitides (sections 6
and 14–16). This observation suggests that some type of activation of the C-terminal
carboxyl group must be accomplished by another enzyme to assist amide bond formation
with the amino group at the N-terminus after leader peptide cleavage. However, the
identities of such activating enzymes have not been confirmed in the gene clusters for
biosynthesis of these circular peptides (Fig. 23). Generally the head-to-tail ligation occurs
between two hydrophobic residues, and membrane bound proteins may be involved. When
either Met1 or Trp70, which are involved in the head-to-tail cyclization of enterocin AS-48,
were substituted with alanine, the amide bond formation still proceeded albeit at lower
production levels.365 Replacement of the last amino acid, histidine, of the leader peptide
with isoleucine blocked formation of AS-48, suggesting that enzymatic recognition of that
residue is essential for the leader peptide cleavage reaction.365 With the exception of the
gene clusters for subtilosin A and SKF, the operons for production of circular peptide
bacteriocins generally contain a membrane-bound protein of unknown function referred to
as DUF95.55 This protein may be involved in the maturation process and/or cyclization.
It is interesting to note that all the gene clusters for the circular bacterial peptides also
contain ATP-binding proteins that could potentially activate the C-terminal carboxyl group
for cyclization, although they may be responsible for other processes involving export. All
the clusters also have a small immunity protein of unknown function that may at least partly
protect the producing organism from its own cyclic antimicrobial peptide.55
13.2 Specific recommendations for bacterial N-to-C cyclized peptides
Historically, a common gene nomenclature has not been adopted for this group (Fig. 23),
except for using the designation “A” for the precursor peptide. Since the “B” designation has
been mostly, but not uniformly, used for the putative membrane protein, we recommend
using this designation for new gene clusters that may be discovered in the future.
14 Amatoxins and phallotoxins
The amatoxins and phallotoxins are produced by several species of mushrooms in the genera
Amanita, Galerina, Lepiota, and Conocybe.54 They are N-to-C cyclized peptides of 7 and 8
residues, respectively, that also contain several other post-translational modifications
including a tryptathionine formed by crosslinking a Cys to a Trp residue (Fig. 24A).366 The
tryptathionine in α-amanitin is oxidized to the sulfoxide and hydroxylated on the indole in
addition to other post-translational modifications such as a bishydroxylated Ile and cis-4-
hydroxyPro. The phallotoxins are structurally similar but have one amino acid less. The
amatoxins potently inhibit RNA polymerase II,367 whereas the phallotoxins such as
phalloidin bind to actin368 and have been used to stain the cytoskeleton. The precursor
peptides contain a 10-residue leader peptide, a 7- or 8-residue core peptide for phallotoxins
and amatoxins, respectively, and a C-terminal recognition sequence (Fig. 24B).22 Based on
genomic survey sequences and chemical characterization, the core peptide of this family of
ribosomal peptides can range in size from 6 to 10 amino acids. Like the cyanobactins and
cyclotides discussed elsewhere in this review, the leader and recognition sequences are
highly conserved, but the core peptide is more variable. Interestingly, the P1 position for
both proteolytic events that excise the core peptide from the precursor peptide is occupied
by a proline. The proteins that carry out cyclization, hydroxylation of Leu, Ile and Pro,
epimerization (for phallotoxins which contain one D-amino acid), and cross-linking of the
Cys and Trp residues are currently still unknown, but a Pro oligopeptidase has been shown
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to cleave the precursor peptides after the Pro residues in an ordered manner,369 just as was
found for the cyanobactins. α-Amanitin is also biosynthesized on ribosomes and initially
processed by a Pro oligopeptidase in Galerina marginata, a mushroom not closely related to
Amanita.370
15 Cyclotides
The name cyclotides was introduced for ribosomally-synthesized peptides from plants that
are characterized by a head-to-tail cyclic peptide backbone and a cystine knot arrangement
of three conserved disulfide bonds.371 They were originally discovered in plants of the
Rubiaceae (coffee) and Violaceae (violet) families but have since also been found in the
Cucurbitaceae (squash) and Fabaceae (legume) families. They are expressed in many plant
tissues, including leaves, stems, flowers and roots. Dozens to hundreds of different
cyclotides are expressed in an individual plant and there appears to be very little crossover
of cyclotides between different plants, i.e., most plants have a unique set of cyclotides.
The prototypic cyclotide, kalata B1, from the African herb Oldenlandia affinis (Rubiaceae)
comprises 29 amino acids, including the six conserved Cys residues that form the signature
cyclic cystine knot (CCK) motif of the family (Fig. 25).372 The backbone segments between
successive Cys residues are referred to as loops and the sequence variations of cyclotides
occur within these loops. Cyclotides have been classified into two main subfamilies, Möbius
or bracelet, based on the presence or absence of a cis X-Pro peptide bond in loop 5 of the
sequence. A smaller, third group is referred to as the trypsin inhibitor subfamily. This third
subfamily has high sequence homology to some members of the knottin family of proteins
from squash plants and its members are also referred to as cyclic knottins.373
Thus far more than 200 sequences of cyclotides have been reported and they are
documented in a database dedicated to circular proteins called CyBase
(www.cybase.org.au).374 They range in size from 28–37 amino acids and are typically not
highly charged peptides. Aside from their disulfide bonds375 and head-to-tail cyclized
backbone, no other post-translational modifications have been found thus far in cyclotides.
Cyclotides appear to be ubiquitous in the Violaceae but are more sparsely distributed in the
Rubiaceae, occurring in about 5% of the hundreds of plants screened thus far. The reports of
cyclotides in other plant families are more recent and there is limited information available
on the distribution of cyclotides in these families. Nevertheless, it appears that cyclotides are
a very large family of plant proteins, potentially numbering in the tens of thousands.376
Cyclotides are gene-encoded and are processed from larger precursor peptides. The
precursors of Rubiaceae and Violaceae cyclotides are dedicated proteins, whose purpose
appears to be only to produce cyclotides. By contrast, cyclotides in Clitoria ternatea, a
member of the Fabaceae family, are produced from a chimeric precursor protein that also
encodes an albumin,377,378 a situation similar to that recently reported for a small cyclic
peptide trypsin inhibitor from sunflower seeds.377 Thus, there appear to be multiple types of
precursors leading to circular proteins in plants. In the case of Rubiaceae and Violaceae
cyclotides, the leader sequence is considered to comprise a pro-region and an N-terminal
region (NTR) that is repeated in some genes along with the adjacent core peptide region, as
illustrated in Fig. 25.
15.1 Biological activities of cyclotides
Cyclotides are thought to be plant defence molecules, given their potent insecticidal activity
against Helicoverpa species.380–383 However, they also have a broad range of other
biological activities, including anti-HIV,384 antimicrobial,385,386 cytotoxic,387
molluscicidal,388 anti-barnacle,389 nematocidal,390,391 and haemolytic activities.392 Some of
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these activities are of potential pharmaceutical interest, and because of their exceptional
stability, cyclotides have also attracted attention as potential protein engineering or drug
design templates.393,394
The diverse range of activities of cyclotides seems to have a common mechanism that
involves binding to and disruption of biological membranes.395 For example, electron
micrographs of Helicoverpa larvae fed a diet containing cyclotides at a similar concentration
to that which occurs naturally in plants show marked swelling and blebbing of mid-gut
cells.380 Larvae that have ingested cyclotides are markedly stunted in their growth and
development, presumably as a result of this disruption of their mid-gut membranes. A range
of biophysical studies396–398 have confirmed membrane interactions for both Möbius and
bracelet cyclotides, and detailed information is available on the residues involved in making
contact with membrane surfaces. Furthermore, electrophysiological and vesicle leakage
studies have confirmed the leakage of marker molecules through membranes treated with
cyclotides. It appears that cyclotides are able to self-associate in the membrane environment
to form large pores.
15.2 Cyclotide biosynthesis
As indicated in Fig. 25, cyclotides are derived from precursor proteins that encode one or
more copies of the core peptide sequences, similar to the precursor peptides for cyanobactins
(section 6) and some orbitides (section 16.3). For example the Oak1 (Oldenlandia affinis
kalata B1 gene) encodes an 11 kDa precursor protein that contains an endoplasmic reticulum
(ER) signal, leader peptide, kalata B1 core peptide, and a C-terminal peptide region, whereas
the Oak4 gene encodes a precursor containing three copies of kalata B2 (Fig. 25).382 The
single or multiple copies of the cyclotide domains are flanked in each case by N-terminal
and C-terminal recognition sequences that are thought to be important for the processing
reactions.
Because of the presence of the ER signal it is believed that cyclotide precursors are probably
folded in the ER prior to processing (excision and cyclization) of the cyclotide domain.
Protein disulfide isomerases (PDIs) are often involved in the folding of disulfide-rich
proteins399 and in vitro experiments have shown increased yields of folded cyclotide kalata
B1 in the presence of PDI,399 although so far there have been no definitive studies on the
involvement of PDI for in planta cyclotide folding. A recent study has shown that cyclotides
are targeted to vacuoles in plant cells and this is where the excision and cyclization
processes are thought to occur.400
The N-terminal repeat (NTR) region of cyclotide precursors has been found to adopt an α-
helical structure as an isolated synthetic peptide,62 but the significance, if any, of this is not
yet known. It has been proposed that it might represent a recognition sequence for cyclotide
folding by PDI, but, interestingly, cyclotide precursors from the Fabaceae plant Clitorea
ternatea lack the NTR region seen in Violaceae or Rubiaceae precursors. The nature of the
processing reaction(s) occurring at the N-terminal end of the cyclotide domain is still
essentially unknown.
However, there is strong evidence that asparaginyl endoprotease (AEP) activity is
responsible for processing at the C-terminal end of the cyclotide domain including
involvement in the cyclization process.401,402 With just one exception (circulin F) all
cyclotides have an Asn or Asp residue as the C-terminal end of the core peptide, and an AEP
is in principle able to cleave after this residue. It has been proposed that this cleavage
reaction occurs contemporaneously with ligation to the earlier-released N-terminus of the
core peptide region. Mutagenesis experiments in transgenic tobacco and Arabidopsis plants
have shown a vital role for the N-terminal Asn residue, as well as other key flanking
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residues.401 Similarly, gene silencing experiments in which AEP activity is knocked down
show decreased production of cyclic peptide in transgenic plants.402 Overall, the processing
of cyclotides can be summarized as involving excision and cyclization from a pre-folded
precursor.
15.3 Specific recommendations for the cyclotide family
At present there is no common gene nomenclature for cyclotide precursors and given the
limited knowledge of the full complement of associated biosynthetic genes encoding
proteins involved in processing it seems premature to propose one. A naming scheme for the
mature cyclic peptides that involves an indicative and pronounceable acronym based on the
binomial name of the plant species in which the cyclotide was first discovered has been
proposed,403 but has not been uniformly followed so far. We recommend that this
suggestion be followed for individual peptide names; this does not exclude the additional
use of ‘family’ names for subgroups of similar cyclotides, for example the cycloviolacins.404
16 Orbitides: plant cyclic peptides lacking disulfide bonds
16.1 Perspective
In 1959, Kaufman and Tobschirble405 reported the discovery of a nonapeptide present in a
slime that had precipitated from a container of flaxseed oil. Curiously, this peptide
composed of proteinogenic amino acids was cyclized by an N-to-C terminal amide bond.
Cyclolinopeptide A, cyclo-[ILVPPFFLI], was the first of more than 168 peptides discovered
in plants with similar structures.198,406 Small plant cyclic peptides consisting entirely of
alpha-amide linkages of natural amino acids were called Caryophyllaceae-like
homomonocyclopeptides in a recent review.198 It is suggested here that the name orbitides
be used to refer to all N-to-C cyclized peptides from plants that do not contain disulfides.
Orbitides are made by at least nine individual plant families including the Annonaceae,
Caryophyllaceae, Euphorbiaceae, Lamiaceae, Linaceae, Phytolaccaceae, Rutaceae,
Schizandraceae, and Verbenaceae. The peptides range in size from five to twelve amino
acids. It is notable that two-amino-acid cyclic peptides from plants have been observed but it
is uncertain whether these arise from a ribosomal precursor.
The 98 Caryophyllaceae-like non-redundant orbitides represented on cybase.org.au
collectively contain 719 amino acids (Spring 2012). Based on simple statistics, many amino
acids are highly underrepresented. Unlike most of the RiPPs discussed in this review,
cysteine is the least abundant amino acid observed in orbitides as it appears just twice in a
single core peptide predicted based on homology with a precursor EST sequence. Acidic
residues (Asp, Glu) and their amides (Asn, Gln), basic residues (Lys, Arg), and His are also
rare. Methionine, while rare overall, is well represented in the amino acids of currently
known orbitides from Linum usitatissimum. Clearly, the amino acid composition of the
orbitides described to date is significantly biased towards hydrophobic amino acids. Glycine
and proline are found in most peptides, and serine, threonine and tyrosine occur 25, 31, and
54 times respectively.
Orbitides are composed largely of unmodified L-amino acids (e.g. Fig. 26) although there
are several exceptions.198 Methionine oxidation is frequently observed in these peptides, but
it has not been determined whether this is a true modification or an artifact of isolation.
Determination of the stereochemistry of the sulfoxide by amino acid analysis may be able to
address this question. Hydroxylated amino acids, including gamma-hydroxy isoleucine and
delta-hydroxy-isoleucine,407,408 have also been observed as well as an unusual N-methyl-4-
aminoproline present in cyclolinopeptide X.409 Additionally, D-tryptophan was observed in
a peptide discovered in Schnabelia oligophylla.410
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The rigid structure of orbitides and low amino acid complexity has enabled extensive
structural studies.198 They have been crystallized from organic solvents, and solution
structure information has been obtained using CD, NMR spectroscopy, and other methods.
The published three-dimensional structures show a single stable conformation for most
orbitides. Prolyl residues may be either in the cis or trans conformation depending on the
peptide, and structures are typically stabilized by internal hydrogen bonds between amide
backbone atoms.198
Only recently has it been shown that these peptides are derived from post-translational
modification of ribosomally synthesized precursor peptides.411 Based on observations of the
apparent segregation of segetalin peptides in closely related varieties of Vaccaria hispanica
and the segregation of peptides in double haploid lines derived from crosses, it was reasoned
that a RiPP origin was possible. A strategy for searching for the genes encoding these
compounds was developed based on sequence tags obtained primarily by tandem mass
spectrometry. The Nor C-terminus of the linear precursor peptide cannot be determined from
the amino acid sequence analysis of the cyclized peptide, therefore, EST libraries were
searched for all possible linear sequences of a peptide.411 Positive hits were found for
cyclolinopeptide G, F and D (Fig. 27) as well as a number of segetalin orbitides. Previously
these sequences had been disregarded due to their small size relative to other sequences.
Expression of a cDNA encoding the precursor sequence of segetalin A in transformed S.
vaccaria hairy roots from the variety White Beauty, which is unable to produce segetalin A,
led to the production of the peptide.411 Furthermore, extracts of developing S. vaccaria
seeds were shown to catalyze the production of segetalin A from a synthetic peptide
precursor representing the gene product. Moreover, the presence of two segetalins, J [cyclo-
(FGTHGLPAP)] and K [cyclo-(GRVKA)] were predicted by sequence analysis of S.
vaccaria cDNA. A focused search by liquid chromatography/mass spectrometry confirmed
the existence of these compounds. Sequence analysis also predicts the presence of similar
precursor genes in Dianthus caryophyllus, Citrus spp., Linum usitatissimum, Gypsophila
arrostil, and Jatropha spp.
16.2 Biosynthesis of orbitides
Searches of EST libraries derived from members of the family Caryophyllaceae has yielded
gene sequences that appear to encode the precursor peptides.411 To date such sequences
have only been observed in Caryophyllaceae mRNA as no genome databases of
Caryophyllaceae species are available. The mRNA sequences are ubiquitously expressed in
many plant tissues and the copy number of these sequences is high relative to other genes.
The mechanism of processing of the precursor peptides is not known at this time. They
typically contain a leader peptide, one core peptide, and a recognition sequence (Table 2).
Caryophyllacaceae orbitide precursor sequences observed thus far exhibit a highly
conserved recognition sequence with nine invariant residues. mRNA sequences of Dianthus
caryophyllus and Gypsophila arrostil encode conservative recognition sequences that are
highly similar, but identification of the cyclic peptides is necessary to confirm that the
mRNAs lead to peptide products. Curiously, an EST sequence from Gypsophila arrostil
contains stop codons and may be a pseudogene (Table 2). The leader sequences of all
observed mRNA sequences that potentially encode RiPPs of caryophyllaceae orbitides
contain 13 amino acids (Table 2).
The sequences of Rutaceae precursor peptides are known from both mRNA and genomic
DNA as genome sequences are available for Citrus sinensis412 and Citrus clementina.413
The observed DNA sequences are short and there are many more potential RiPP coding
sequences than known peptides. The recognition sequence is highly conserved in both length
and amino acid composition (Table 2), whereas the leader sequences are more variable.
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16.3 Biosynthesis of orbitides in Linaceae
The genomic and mRNA sequences from the flaxseed variety Linum usitatissimum cv
Bethune have been determined.414,415 Blast searches of EST sequences derived from this
cultivar using a search string based on the known amino acids of cyclolinopeptide G
revealed a sequence that potentially includes five core peptides in a single precursor peptide
(Fig. 27).416 Three of these sequences corresponded to cyclolinopeptide G. The ability of a
single precursor to be processed to multiple cyclic peptides is unique among known
precursor peptides of orbitides but is also found in the precursors to cyclotides (section 15),
cyanobactins (section 6), and possibly microviridins (section 11). A search of a genome
database that comprised shotgun sequences of Bethune flax using the polyRiPP precursor
sequence revealed both the DNA sequence that encodes cyclolinopeptides D, F and G (Fig.
27) as well as an additional sequence that encodes a polyRiPP precursor that may be
processed to cyclolinopeptides A, B and E.416
16.4 Biosynthesis of orbitides in Euphorbiaceae
The interest in Jatropha curcas as a potential biofuel crop has resulted in generation of a
substantial database of EST sequences and a genomic sequence is also available.417 A
search of EST libraries produced from Jatropha curcas conducted for this review identified
two mRNA sequences that encode the two known cyclic peptides previously isolated from J.
curcas, curcacyclines A and B.418 These sequences have no C-terminal recognition
sequence as the gene terminates with the core peptide, thus requiring activation of the C-
terminal carboxylate, similarly to the bacterial N-to-C cyclized peptides discussed in section
13. The leader sequences of both peptides contain 36 amino acids and are highly conserved
(Table 3). Many other cyclic peptides have been isolated from Jatropha,419 and may have a
RiPP origin.
16.5 Relationship to other RiPP subfamilies
Orbitides have been observed in a range of plant tissues including roots, stems, leaves,
developing seeds, mature seeds, fruits, and peels,198 and the corresponding mRNA has been
detected in the various plant tissues. To date over one hundred unique peptides have been
discovered, but only a small number of the species that are likely to produce them have been
surveyed. Combined the families of Rutaceae, Linnaceae, Caryophyllaceae, Verbenacea,
Annonaceae, Lamiaceae, Phytolaccaceae, Euphorbiaceae, and Schizandraceae have
thousands of members.420 It is probable that a thorough study will reveal hundreds if not
thousands of additional peptides.
Although the cyclotides and orbitides appear to be quite different in size, structure, and
primary composition there is a striking similarity in gene organization between the
cyclotides and the orbitides from flax (cyclolinopeptides). Genes in both groups comprise, at
the carboxy terminal end of the gene, multiple copies of the cyclic peptide sequences
flanked by highly conserved regions. In contrast DNA sequences that comprise orbitides
from Caryophyllacea genera such as Vaccaria and Rutaceae genera such as Citrus comprise
the highly conserved flanking sequences but contain only a single cyclopeptide sequence.
This apparent difference in gene structure could result from the fact that the published
Vaccaria and Citrus sequences were only derived from mRNA and as such may only
represent pieces of pre-mRNA from a more complex gene. This possibility is supported by
the fact that the majority of these DNA sequences are lacking a methionine amino terminus
of the precursor peptide and the cDNAs of those that do have an intact amino terminal
portion do not have features such as a tata-box expected in a promoter. The sequences
flanking the precursor peptides have a high AT content and features typical of introns.
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It is noteworthy that despite the relatively extensive size of the flax EST library and the
abundance of cyclolinopeptides A, C and E, the mRNA from this gene has not been found
and the gene was only uncovered when the genomic sequence of flax was determined. The
unusual structure of the mRNAs from these genes apparently precludes discovery by
standard cloning methodology. In consideration of this issue, and very few genomic
sequences that are yet available, it is possible that the organization of the genes in other
plant families that are known to make orbitide type cyclopeptides will be similar to that of
the cyclotides and the orbitides from flax.
16.6 Biological activity
The innate biological role of orbitides is currently unknown. Generally the lipophilic
composition of the orbitides is consistent with a membrane active role.421 Attention has
largely been focused on the use of these compounds as drug candidates and in
agriculture.198 Preparations containing orbitides have been tested using a number of
bioassays that do not always relate to mechanism of action. For example, orbitides are
classified as cytotoxic, antiplatelet, antimalarial, immunomodulating, and inhibiting T cell
proliferation.198 These assays provide promising leads to understanding biologial activity
and potential applications of the peptides, but a universal mechanism of action is unlikely.
Analysis of the effects of peptides using in vitro assays has lead to a more precise
understanding of the possible mechanism of action of some peptides. Curcacycline B
enhances prolyl cis–trans isomerase activity of human cyclophilin B,422 and
cycloleonuripeptide D inhibits cyclo-oxygenase.423 Structure activity studies of
pseudostellarin A showed that γ- and β- turn structures were fixed by trans-annular
hydrogen bonds between Gly and Leu.424 This rigid conformation was hypothesized to be
important in tyrosinase activity exhibited by this compound. Similarly, the Trp-Ala-Gly-Val
sequence in segetallin A and B has been suggested to play an important role in their
estrogen-like activities.425
16.7 Specific recommendations for the orbitide family
We propose that the name “orbitide” replace the longer designation “Caryophyllaceae like
homomonocyclopeptides” and is used for all plant N-to-C cyclized peptides that do not
contain disulfide crosslinks. It is too early to classify the various orbitides when so few
confirmed examples are available.
17 Conopeptides and other toxoglossan venom peptides
The venoms of predatory marine snails (such as species in the genus Conus, the cone snails)
are a complex mixture of ribosomally-synthesized peptides that are post-translationally
modified to various extents.426 Although the possibility that these venoms may also contain
gene products from bacterial symbionts cannot be completely excluded, the vast majority of
peptides are encoded in the genome of the marine snail itself, expressed in the epithelial
cells lining the venom duct, and secreted into the lumen of the duct. Transcriptome analyses
that provide quantitative estimates of the mRNAs expressed in the snail’s venom duct
typically reveal that a major fraction of all transcripts encode the secreted venom peptides
(see for example ref. 10, 427, and 428).
Biologically-active peptides from animal venoms are an increasingly important class of
natural products.429 In total, these comprise many millions of different peptides, each
presumably evolved to alter the function of a specific physiological target. Like the other
RiPPs discussed in this review, venom peptides are generally post-translationally processed
from larger precursors, to yield peptides that are mostly in a size range of 30–90 amino acids
after processing.24 The venom peptides evolved by marine snails differ from most animal
Arnison et al. Page 31
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
venom peptides in several distinct ways. The best characterized of the marine snail peptides,
those of the cone snails (generally known as conopeptides or conotoxins) are mostly smaller
(10–30 amino acids), with a significantly higher density of disulfide crosslinks than most
animal venom peptides. Another feature is the larger diversity of post-translational
modifications in these peptides compared to other venom peptides (e.g., scorpion or snake
peptides).426 This diversity of post-translational modifications make them more like the
RiPPs from bacterial and plant sources.
As detailed below, marine snail venom peptides have an entirely different set of post-
translational modifications compared to other RiPPs. One likely fundamental cause for the
lack of overlap in PTMs is that the evolution of post-translational modification in marine
snail venom peptides has followed a very different path from post-translational
modifications of peptidic natural products produced by bacteria. In the evolution and
adaptive radiation of venomous animals, a delivery system must be evolved; thus, venoms
are intrinsically injectable mixtures of natural products. Since a delivery route has already
been established when the pharmacological agents in venoms are being evolved, peptides
and polypeptides that suit the biological purposes of the venomous animal can immediately
be selected for. In general, there are no major barriers to delivery of peptides and
polypeptides once venom is injected into the targeted animal and most molecular targets are
plasma membrane proteins. Thus, post-translational modifications are presumably evolved
primarily to increase potency and selectivity, rather than to improve the efficiency of
delivery, which may have been an evolutionary driving force for bacterial RiPPs.
As a class, marine snail peptides are structurally extremely diverse, and a comprehensive
discussion of all of the structural and functional subclasses that have been described would
require a much longer exposition than warranted in the present overview. Venom peptides of
marine snails run the gamut from ribosomally-synthesized peptides that are quite minimally
post-translationally modified, to peptidic natural products that have been subjected to more
diverse post-translational modifications than most other RiPPs. The different post-
translational modifications that have been reported in conopeptides to date are shown in
Table 4. One feature that makes the literature on molluscan venom peptides particularly
confusing compared to the other RiPPs discussed in this review is that the nomenclature in
use names these peptides on the basis of their functional specificity and taxonomic origins,
rather than their structural and/or chemical features.
17.1 Biological and toxicological perspectives
Venomous marine snails comprise a forbiddingly complex assemblage of >10 000
species.430 Taxonomists typically refer all venomous species to a single superfamily
(“Conoidea”) or suborder (“Toxoglossa”), referred to as “conoideans” or “toxoglossans.”
This is likely the most species-rich of all molluscan lineages with a large number of
extremely small, deep-water forms that mostly remain undescribed. Venoms of all
toxoglossans are produced in a specialized venom duct; the analysis of any individual
venom has invariably demonstrated that it is a complex mixture with essentially all of the
biologically-active components being peptides. Although, cone snails (genus Conus or
family Conidae) comprise less than 5% of the total biodiversity of venomous molluscs,
greater than 99% of all published papers in the scientific literature concern peptides derived
from cone snails.
A nomenclature for peptides from other lineages of venomous marine snails has recently
been suggested, based on family groups within the superfamily Conoidea. Thus, in addition
to conopeptides from cone snails, venom peptides from species in the family Turridae are
referred to as turripeptides, and from the family Clathurellidae as clathurellipeptides, etc.
(12 other family groups have been proposed).431,432 Very few venom peptides from
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toxoglossans other than the cone snails have been characterized, and these mostly conform
to the generalizations about conopeptides that we outline below. Because conopeptides have
been much more extensively investigated, our focus will be on these peptides, but the reader
should be aware of the vast trove of uncharacterized, post-translationally modified peptides
from the other toxoglossan lineages.
One general feature of all marine snail venoms is their complexity both in the number of
different peptides found, as well as in their structures. Furthermore, the genes encoding
these venom peptides undergo accelerated evolution, so that there is essentially no molecular
overlap in the modified core peptides found in venoms of even closely-related cone snail
species. Most genes that encode these peptides have introns, and the initial transcripts have
to undergo splicing before the mRNA can be exported from the nucleus. A small minority of
modified core peptides are apparently encoded by genes without introns.
The translated precursor peptides have the canonical organization characteristic of RiPPs,
with the leader peptide varying considerably in size; most conopeptide precursor peptides
are 70–120 amino acids, and the majority of well-characterized modified core peptides
found in cone snail venoms fall in the range of 12–30 amino acids. One unique feature of
conopeptide superfamilies is the remarkable conservation of signal sequences within all
members of the superfamily, providing an unequivocal marker for the gene superfamily to
which a specific venom peptide belongs. Although there may be 50–200 different
conopeptides found in the venom of an individual species, the vast majority of these
typically belong to only 5–8 superfamilies.
17.2 Conopeptide structures and biological activities
Conopeptides comprise a more or less continuous spectrum of post-translational
modification, with several widely distributed in all animal venom peptides: proteolytic
cleavage, disulfide bond formation, C-terminal amidation, and cyclization of N-terminal Gln
residues to pyroglutamate. Some small, disulfide-rich, endogenous peptides such as
endothelin are similar in their general biochemical characteristics to many conopeptides. A
superfamily of larger conopeptides (called conkunitzins) have clearly co-opted a well-
characterized endogenous structural framework known as the Kunitz domain, which is
widely found in protease inhibitors such as bovine plasma trypsin inhibitor (BPTI). Some
venom peptides are expressed in other tissues of the cone snail, presumably with
endogenous physiological functions (e.g., the conopressins). However, the origin of the
majority of conopeptide superfamilies has not been established and in contrast to snake
toxins and scorpion peptides that have 1–2 conserved structural frameworks, each gene
superfamily represents at least one distinctive structural fold.
Many conopeptides have a surprising array of diverse covalent modifications, each carried
out by a different post-translational modification enzyme. One notable difference from
RiPPs from bacteria and archaea is that they are encoded by eukaryotic genes that are not
organized in a biosynthetic gene cluster. Adding to the complexity is that in a number of
cases, peptides that are post-translationally modified at a particular locus are found in the
venom along with the corresponding peptide with the identical amino acid sequence that has
not been post-translationally modified. This trend is particularly observed for hydroxylation
of proline to 4-hydroxyproline. The functional significance of the incomplete penetrance of
some post-translational modifications has not been critically assessed.
For most conopeptides, the most important structural feature that confers the correct three-
dimensional conformation to the biologically-active peptide are disulfide bonds.
Conopeptides can have an unprecedented density of disulfide crosslinks; some conopeptides
are only twelve amino acids in length, with three disulfide crosslinks. Since six Cys residues
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forming three disulfides can generate fifteen distinct isomers, the oxidative folding pathway
of an unmodified core peptide to the specific biologically-active disulfide crosslinked isomer
may well be enzyme catalyzed.433 This “conotoxin oxidative folding problem” is a
challenging issue that has not been mechanistically elucidated, and it is likely that formation
of the correct disulfide crosslinks in conotoxins requires special post-translational enzymes
and accessory factors.
The pharmacological characterization of conopeptides to date has demonstrated great
diversity of targets. A large majority of the molecular targets of conopeptides that have been
elucidated are ion channels and receptors present on the plasma membrane; many are
expressed in nervous systems. Thus, conopeptides have become a mainstay of ion channel
pharmacology,434 and are widely used as basic research tools in neuroscience.
It is perhaps easiest to illustrate the range of conopeptide functional and structural diversity
by focusing on their direct biomedical applications. At present, several conopeptides have
been developed as lead compounds for therapeutic drugs, and one conopeptide is an
approved commercial drug in the U.S. and European community (Prialt, for intractable
pain). Some of the conopeptides that have reached human clinical trials are shown in Fig.
28.435 They demonstrate the structural and functional diversity in this compound family.
Two of the peptides in Fig. 28, contulakin G and conotokin G, both characterized from the
venom of Conus geographus, reached Phase I clinical trials for pain and epilepsy,
respectively. Contulakin G has a glycosylated threonine residue that is essential for its
potent analgesic activity. It is targeted to a G-protein coupled receptor (the neurotensin
receptor) and has striking sequence homology at its C-terminal end to neurotensin.
Interestingly, although the glycosylation makes the peptide less potent as an agonist at the
neurotensin receptor, it renders the peptide a more effective analgesic. Fig. 28 also shows
the structure of a modified conopeptide χ-MrIA that is in clinical development and inhibits
the norepinephrine transporter; this analgesic peptide has been re-engineered by chemists to
introduce a modification (pyroglutamate) in addition to the preexisting two disulfide bridges
and 4-hydroxy-Pro found in the native peptide isolated from Conus marmoreus.
17.3 The conantokin superfamily and γ-carboxylation of glutamate
Although the three-dimensional conformation of most modified conopeptides is determined
by the pattern of disulfide crosslinking, a notable exception are members of the conantokin
superfamily, including conantokin G (Fig. 28).436 Conantokin G is an NMDA receptor
antagonist, highly selective for one particular subtype of this receptor (i.e., receptors with
NR2B subunits). For all conantokin peptides, an unusual post-translational modification, the
carboxylation of glutamate residues to form γ-carboxyglutamate (γ or Gla) is required.
When these modified amino acids are spaced every three or four residues apart in the
primary amino acid sequence, the peptide folds into a stable helical conformation in the
presence of Ca2+.437 In essence, the modification of glutamate to γ-carboxyglutamate
creates a functional group for coordinating Ca2+; Two adjacent Gla residues on the same
side of a helix chelate Ca2+ in a manner analogous to EDTA or EGTA. Thus, the post-
translational modification of glutamate residues by the enzyme γ-glutamyl carboxylase is
essential for the biologically-active conformation of conantokin G.
A similar motif is found in many of the proteases comprising the mammalian blood-clotting
cascade (such as prothrombin). The presence of a domain containing Gla residues is
essential for the accumulation of blood-clotting factors on the membranes of activated
platelets, thereby triggering the formation of blood clots. However, in mammals this
modification is only found in large proteins. Among RiPPs, the γ-carboxylation of glutamate
appears to be unique to toxoglossan venom peptides (the presence of this modification has
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been established both in conopeptides, and in certain turripeptides from venomous snails in
the family Turridae).
17.4 Biosynthesis of conopeptides
The enzyme converting glutamate to Gla is a highly-conserved, widely-distributed
enzyme.438,439 Not only do the enzymes that carry out this modification in cone snails and
in the mammalian blood-clotting system have high sequence similarity, they are also
functionally homologous—both require reduced vitamin K as a cofactor, and are stimulated
by binding to a recognition sequence that determines which glutamate residue will be
modified. An even more unexpected and striking piece of evidence for the common
evolutionary origin of these enzymes was the discovery that the ten different introns in the
human gene are completely conserved in their location in the Conus gene. Thus, if an intron
is found between codons in the human gene, it is also found between the homologous
codons in Conus. If an intron is between the second and third nucleotide of a codon in the
human gene, it is in precisely the same location as the homologous codon in the Conus gene
sequence. The introns themselves have no detectable sequence similarity, and the cone snail
introns are longer than those in humans.
Interestingly, the same enzyme was identified in Drosophila (where its function is
unknown); in the Drosophila gene only three introns remain (all at precisely conserved
locations), and they are all shorter than either the corresponding mammalian or Conus
introns. Thus, in this instance, the post-translational modification enzyme that the cone
snails have recruited for one gene superfamily of RiPPs is clearly an ancient enzyme with its
origins early in metazoan evolution. It has been speculated that because the post-
translational modification promotes the formation of short α-helices, that the carboxylation
of glutamate is a relict of a pre-cellular, pre-ribosomal biotic world. This one case of a well-
characterized post-translational enzyme that acts on conopeptides suggests that the PTMs
used in marine snail venoms were already present early in evolution, and subsequently
recruited in the snails venom duct for novel biological purposes.
18 Glycocins
The glycocins are a small group of glycosylated antimicrobial peptides produced by
bacteria. The two currently characterized members, sublancin 168 produced by Bacillus
subtilis 168 and glycocin F produced by Lactobacillus plantarum KW30, are both
glycosylated on Cys residues,440,441 a very unusual form of glycosylation. In sublancin, a
glucose is attached to one of five Cys residues in the precursor peptide (Cys22) with the
other four Cys residues engaged in two disulfides (Fig. 29). Glycocin F has a very similar
arrangement of disulfide bonds as well as a connecting loop that is glycosylated, but an N-
acetylglucosamine is conjugated to a Ser in this loop rather than to a Cys residue. The S-
linked glycosylation in glycocin F is located on a Cys that is the last residue of the peptide.
The NMR structure of glycocin F has been reported showing two alpha helices held together
by the two disulfide linkages.442 These two helices also appear to be the recognition
elements for the S-glycosyl-transferase SunS involved in sublancin formation.443 This
glycosyltransferase has specificity for Cys because a Cys22Ser mutant of the SunA
precursor peptide was not accepted as substrate.440 However, the enzyme was promiscuous
with respect to its nucleotide-sugar donor and could add a variety of different hexoses to
Cys22. Furthermore, SunS glucosylated mutant peptides in which the position of the Cys
was varied along the loop connecting the two helices.443 Hence, it appears that as long as
one or more Cys residues are present in this loop, SunS will carry out the S-linked
glycosylation. Unlike most biosynthetic enzymes discussed in this review, SunS does not
require the leader peptide for its activity.440 Whether one or more glycosyltransferases are
Arnison et al. Page 35
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
responsible to install the two glycosylations in glycocin F is currently not known.
Furthermore, the mode of action of sublancin 168 and glycocin F has yet to be established.
18.1 Recommendations for the glycocin family
The glycocin family currently encompasses both O- and S-linked bacterial glycopeptides
with antimicrobial activities. Although at present both members contain S-linked sugars, the
name glycocin is not limited to S-linked glycopeptides as future studies may reveal new
members that only contain O-linked and/or N-linked carbohydrates. The suffix –cin in
glycocin presently limits the family to antimicrobial peptides. It is possible that additional
bacterial glycosylated peptides with other functions are awaiting discovery in which case a
broader nomenclature may be required, similar to the extension of lantibiotics to
lanthipeptides and sactibiotics to sactipeptides. The designation “A” is recommended for the
precursor peptides and the designation “S” for the glycosyltransferase, “I” for self-resistance
proteins, “T” for transporters, and “B” for thiol-disulfide isomerases.
19 Autoinducing peptides, ComX, methanobactin, and N-formylated
peptides
The autoinducing peptides (AIPs) are quorum sensing peptides produced by most members
of the low G + C Gram-positive bacteria (Firmicutes).444–446 In all of these AIP signals, the
presence of a cyclic ester or thioester is a conserved feature, which differentiates the AIP
structures from linear regulatory peptides. The Staphylococcus aureus AIPs have received
the most attention, and in producing strains the extracellular AIP binds to a receptor on a
cognate AgrC histidine kinase, inducing a regulatory cascade that increases expression of
virulence factors.447 The S. aureus thiolactone-containing peptide is generated from a larger
precursor peptide AgrD (Fig. 30A) by AgrB,448,449 a unique transmembrane protein that has
endopeptidase activity.449–451 The molecular details of the thiolactonization process are
currently not known but the general process of excision of a cyclic peptide from a linear
precursor has similarities with the cyclization processes described for the cyanobactins,
amatoxins, cyclotides, and some orbitides. The ArgD peptides are about 45 amino acids in
length and contain three different regions: an N-terminal amphiphatic helical region,452 a
core peptide that encodes the residues that will form the mature AIP,448 and a C-terminal,
highly negatively charged region.449 The N-terminal helix is thought to be important for
interaction of the peptide with the membrane and with AgrB. Overall, there is considerable
variation in the sequences of the three regions in different species with only the Cys required
for thiolactone formation (or Ser for lactone formation) conserved in the core peptide. The
negatively charged C-terminal putative helix is more conserved than the N-terminal helix.449
Another example of ribosomally synthesized quorum sensing compounds are ComX and its
derivatives produced by bacilli. These compounds are biosynthesized from a much longer
precursor peptide that contains a leader peptide and a variable core peptide (Fig. 30B). After
unusual prenylation and cyclization steps involving a fully conserved Trp residue (Fig.
30B),453 the leader peptide is released and the mature compound is produced.454
Methanobactins are copper chelators, or chalkophores (cf. siderophores for iron chelators)
that are used by methanotrophic bacteria that use methane as their sole carbon source.
Copper acquisition is critical for these Gram-negative bacteria as methane oxidation is
carried out by a copper-dependent monooxygenase.455 The initially reported structure of the
methanobactin isolated from Methylosinus trichosporium OB3b determined by X-ray
crystallography456 has been revised on the basis of NMR studies and more recent high
resolution X-ray structures (Fig. 31).457,458 It contains two oxazolones and a disulfide.
When the genome of M. trichosporium was sequenced, a small gene was identified that
Arnison et al. Page 36
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
encodes for a peptide that could serve as the precursor for methanobactin (Fig. 31). The
peptide contains a putative 19-amino acid leader peptide and a 11-amino acid core
peptide.459 If this is indeed the precursor to methanobactin, post-translational modifications
must involve transformation of two of the Cys residues to the oxazolones with an adjacent
thioamide, deamination of an N-terminal Leu, and formation of the disulfide. Interestingly,
homologous precursor peptide genes and flanking genes occur outside the methanotrophs,
such as in the rice endophyte Azospirillum sp. B510.459 Further studies may provide insights
into this fascinating system.
Peptidogenomic approaches have uncovered several short N-formylated linear peptides.6
Bacterial proteins are typically formylated on the N-terminal Met residue, because
translation initiates with formyl-methionine. The formyl group is usually removed by a
peptide deformylase, but in some short peptides, the deformylation step appears to be
incomplete or omitted altogether. In most cases, the functional relevance is unclear and the
lack of deformylation may simply be the result of translation termination before the short
peptide emerges from the ribosome to be deformylated. But in the case of the formylated δ-
toxin of Staphylococcus aureus, deformylation appears to be inhibited by depletion of iron
during stationary phase.460 Furthermore, the formylated toxin, as well as other N-formylated
peptides,461 serves as a chemoattractant for neutrophils.460 N-Terminal formylation is also
found in microcin C discussed above. It is possible that N-formylation helps protect the
peptides from aminopeptidases, similarly to other modifications of the N-terminus found in
other RiPPs (e.g. acetyl,462 lactyl,140,146 methyl,150,180,181,463 2-oxobutyryl,163 and 2-
oxopropionyl464). We note that N-formylated peptides are not RiPPs since they are not post-
translationally modified, but they are included here as they are often detected when
searching for RiPPs by mass spectrometry.
20 PQQ, pantocin, and thyroid hormones
A number of other molecules that are smaller than the compounds discussed thus far are
generated from a ribosomally synthesized peptide. Pyrroloquinoline quinone (PQQ, Fig.
32A) is a cofactor for several bacterial dehydrogenases.465 In a series of studies in the late
1980s and early 1990s, PQQ was first shown to be generated from a ribosomally synthesized
precursor peptide.466–468 Currently, the biosynthetic genes have been found in over 100
bacteria.8 The precursor peptide is PqqA, a 22 amino acid peptide containing a conserved
glutamate and tyrosine that are oxidatively morphed into the final structure and excised from
the peptide by a series of enzymatic reactions (Fig. 32A).466,469 Genetic studies have
implicated PqqACDE to be required for PQQ biosynthesis,8,470,471 but the details of the
PTM process are largely unknown. PqqC has been shown to catalyze the final oxidation step
in an oxygen dependent mechanism.472 PqqB and PqqE, a putative non-heme iron
oxygenase and a radical-SAM protein respecutively, carry out currently unknown
transformations.8,473 PqqE and PqqD form a protein complex that may be important for the
overall timing of the reactions and/or the protection of reactive intermediates.8,474 Although
PqqF is not absolutely required, its sequence places it in the zinc-dependent protease family
and it may be involved in the peptide excision process. At present the role of the flanking
amino acids in the PqqA precursor peptide is not known, but it is likely that they serve a
similar function as the recognition sequences discussed for cyanobactin, amatoxin, and
cyclotide biosynthesis. With only two, non-sequential amino acids of the precursor peptide
ending up in the final product, the term core peptide is not pertinent. As mentioned before,
PQQ is made by an overall process that is similar to the other RiPPs discussed here, but the
final product is no longer a peptide.
Another potential small molecule excised from a larger protein is coelenterazine (also called
coelenterate-type luciferin, Fig. 32B). This molecule is used as a light emitting substrate by
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various luciferases and Ca2+-binding photoproteins in marine organisms. It is not well
defined what organisms produce coelenterazine and its biosynthesis is currently unresolved.
However, two observations suggest it may be ribosomally synthesized. First, feeding
experiments indicate the compound is made from L-Tyr and L-Phe.475 Second, and more
intriguing, expression in E. coli of a mutant of the green fluorescent protein from Aequorea
victoria in which the conserved sequence FSYG leading to the GFP chromophore was
replaced with FYYG resulted in the production of coelenterazine.476 At present, no details
are available regarding this remarkable observation, but it suggests that coelenterazine can
be made from a ribosomally synthesized protein.
Another example of a small molecule produced from a much larger ribosomally synthesized
precursor is pantocin A produced by the bacterium Pantoea agglomerans (Fig. 32C).477 The
gene paaP in its biosynthetic cluster encodes a 30-residue peptide with the sequence -Glu-
Glu-Asn- near its center.478 Mutagenesis and heterologous expression studies demonstrated
that the final product is formed from PaaP by two enzymes, PaaA and PaaB, and unknown
proteases in the host.478 PaaA has significant sequence similarity to the ThiF/MoeB family
of proteins that adenylate carboxyl groups, hinting that it may be involved in cyclization of
the side chain of the first Glu with the amide nitrogen of the second Glu residue. PaaB has a
domain with homology to the Fe(II)-α-ketoglutarate dependent family of enzymes,
suggesting it may catalyze an oxidation step that will be required for formation of the final
product. As with the PQQ pathway, the roles of the flanking residues in the precursor
peptide is not clear but they may be recognition sequences for PaaA and PaaB, and like
many leader peptides, they may keep the biosynthetic intermediates inactive.
Perhaps the most remarkable example of construction of a biologically active small
molecule from a ribosomally synthesized precursor is the assembly mechanism of the
thyroid hormones 3,3′,5,5′-tetraiodothyronine (T4) and 3,30,5-triiodo-thyronine (T3) (Fig.
32D). These compounds are not made from free Tyr but rather from Tyr imbedded in
thyroglobulin, a very large glycoprotein comprised of two identical subunits of 330 000 Da
each.479 The aromatic rings of proximal Tyr residues are diiodinated by thyroid peroxidase,
and this enzyme subsequently carries out the oxidatively coupling reaction of two iodinated
Tyr residues. Hydrolysis then releases T4 and a small amount of T3 from incompletely
iodinated Tyr. Since T3 is the major active form, T4 is converted to T3 by iodothyronine
dei-odinases.479 Although clearly this biosynthetic pathway is very different from that of the
other compounds discussed in this review, the thyroid hormone examples provide yet
another demonstration of the diverse ways that nature makes use of ribosomal products to
generate small molecules.
21 Shorthand linear notations for RiPPs
As a consequence of their generally large molecular structures, shorthand nomenclature has
been introduced for several of the subclasses of RiPPs (e.g. for lanthipeptides in Fig. 4).
Here, we suggest a more general shorthand notation that can represent structures of RiPPs in
linear format, which is useful for description of structures in abstracts of manuscripts and
conference proceedings. The proposed notation uses a prefix code of 3–4 characters used to
specify the type of modification for each modified amino acid, which are identified by their
residue number in the core peptide sequence. For instance, 1-NαAc refers to acetylation of
the N-terminus of residue 1 (e.g. in microviridin B, Fig. 33), 22-ΔCO2 refers to
decarboxylation of residue 22 (e.g. gallidermin, Fig. 33), and 1-CγOH refers to
hydroxylation of the γ-carbon of residue 1 (e.g. α-amanitin, Fig. 34). For post-translational
modifications that introduce crosslinks, the amino acids that are crosslinked are indicated
first by residue number followed by the type of crosslink. For instance, 3R-7-CβS refers to a
crosslink between the β-carbon of amino acid 3 and the sulfur of residue 7, with the
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stereochemistry at Cβ being R (e.g. the A-ring of nisin, Fig. 33), 1-8-NαC refers to N-to-C
cyclization between the N-terminal amino group of residue 1 and the C-terminal carboxylate
of residue 8 (e.g. patellamide C, Fig. 33), 5-19-SS refers to a disulfide between residues 5
and 19 (e.g. kalata B1, Fig. 34), and 4-31-SCα refers to a crosslink between the sulfur of
residue 4 to the α-carbon of residue 31 (e.g. in subtilosin, Fig. 34). All modifications in a
given peptide are provided in front of the linear sequence of the core peptide in square
brackets starting with the lowest residue numbers and working towards the higher residues.
When multiple identical modifications are present, they are grouped together as illustrated
for the five (methyl)lanthionine cross-links in nisin (Fig. 33). The prefixes for a select
number of PTMs discussed in this review are listed in Table 5, and examples of select RiPPs
are shown in Fig. 33 and 34. Using the same reasoning, new prefixes can be readily
introduced for the many PTMs that are not covered in Table 5.
It is likely that the future will see more and more engineered, non-natural RiPP analogs
having one or more amino acid substitutions, insertions, or deletions. Such molecules should
be denoted by standard mutagenesis nomenclature. Analogs containing additional modified
residues by in vitro synthesis or by synthetic biology approaches can in most cases also be
designated by the standard nomenclature, e.g. a Met residue that is replaced by a chlorinated
Trp residue at postion 17 in nisin would be designated as Met17ClTrp. In cases where
modifications from different RiPP classes are combined into one molecule (e.g. a classical
lantibiotic attached to a lasso-peptide-like ring), the new molecule should get a descriptive
name (e.g. nisin[1–18]-GSG linker-capistruin[1–9]), accompanied by a description of the
structure at the amino acid level according to the proposed nomenclature rules described in
this paper. Use of newly invented names, such as lassonisin or micronisin to describe
hybrids are discouraged as they would cause possible confusion, especially if many such
analogs are prepared.
22 Outlook
The ribosomal origin of some of the classes of RiPPs discussed in this review has been
known for quite some time, but for most classes this realization has been reached more
recently as a result of the rapid advancement of DNA sequencing techniques. The
availability of genome sequences first allowed the identification of putative precursor genes
for known natural products. For compounds of bacterial, archaeal, and fungal sources, the
convenient clustering of genes also provided immediate insights into the biosynthetic
pathways, but deciphering biosynthetic pathways has been more challenging for compounds
from higher organisms. In recent years, the use of genome information has been shifting
slowly from identification of the genes for the biosynthesis of known compounds to genome
mining for new compounds.1 RiPPs are particularly suited for genome mining because of
the direct link between precursor gene and final product and because of the relatively short
biosynthetic pathways, which lend them well for heterologous expression. This approach has
allowed both isolation of new compounds from producing
organisms,6,26,47,48,64,133,134,144,179,190,192,308,327,480,481 and heterologous production of
compounds that are not produced under laboratory conditions by the organism containing
the biosynthetic genes (“silent or cryptic clusters”).89 These studies either used genes
encoding related precursor peptides as query for searching genomes, resulting in analogs of
known compounds, or used the genes encoding key biosynthetic enzymes, often resulting in
more distant analogs of known natural products.
Although they have been quite successful, these genome mining strategies currently have
two disadvantages. Unlike phenotypic screens for discovery of new natural products with a
known bioactivity, the genome mining approach typically does not provide any clues about
the biological activities of the products. A second current shortcoming of the genome
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mining approach is that compound classes that fall into new structural scaffolds are difficult
to discover because neither their biosynthetic genes nor their precursor genes are known.
The large number of short open reading frames in genomes that are not annotated during
genome sequencing exercises suggests that such classes may be quite common. Even with
these current limitations, genome mining is likely to become an even more active area of
research that potentially may uncover compounds with exciting bioactivities because
analysis of the currently available genomes for known classes illustrates the ubiquitous
nature of RiPPs. Going forward, it will be important to use the most powerful bioinformatics
methods to analyze the explosion of sequence information. In this respect, Hidden Markov
Models (HMMs) can identify distantly related protein families when other methods do
not.482–484 The recently developed, freely available genome mining tool Bagel2 (http://
bagel2.molgenrug.nl/) also offers many features to screen for putative (modified)
antimicrobial peptides based on a large set of search criteria.485 Another useful site in the
context of post-translational modifications is the RESID Database of Protein Modifications
(http://www.ebi.ac.uk/RESID/index.html),486 which provides a comprehensive compilation
of naturally occurring modifications annotated in the UniProt Protein Knowledgebase.
Caution is warranted with respect to drawing conclusions from bioinformatics alone as
several common expectations about RiPP biosynthesis systems are not completely reliable.
In particular, sequence similarity of precursor peptides does not guarantee that the final
products belong to the same family of RiPPs. For example, lanthionine synthetases, cyclo-
dehydratases, and radical SAM enzymes all act on members of the nitrile hydratase-like
leader peptide family, as well as the nif11-like leader peptide family.3,26,45 Meanwhile,
proximity between genes for a RiPP precursor and a maturase does not guarantee a target/
substrate relationship. The genes encoding the precursor peptide, its maturation enzyme(s),
and its export transporter can all be far apart in a genome.26,487
This review has attempted to bring together groups of scientists working on different classes
of RiPPs to work out a common nomenclature within the class and across classes. We hope
that similar concerted efforts will be used to classify new RiPP classes and their biosynthetic
machinery that are yet to be discovered. In particular, we recommend in general that the
gene encoding the precursor gene is always given the designation A. If surrounding genes
have homology with enzymes used by the RiPP classes discussed in this review, we
recommend trying to use a similar gene designation as that used previously to illustrate the
connection. For all genes encoding proteins with unknown function, we recommend
alphabetically naming the genes in the order they appear in the operon in the first disclosure
of the gene cluster. All studies following the initial report of a new RiPP are strongly
encouraged to use the same letter designations of the initial study such that a common
nomenclature arises.
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Fig. 1.
General biosynthetic pathway for RiPPs. The precursor peptide contains a core region that is
transformed into the mature product. Many of the post-translational modifications are
guided by leader peptide and the recognition sequences as discussed in this review for
subclasses of RiPPs. Products of eukaryotic origin also often contain an N-terminal signal
peptide that directs the peptide to specialized compartments for modification and secretion.
C-terminal recognition sequences are sometimes also present for peptide cyclization (e.g.
see sections on cyanobactins, amatoxins, cyclotides, and orbitides). In the case of the
bottromycins, a leader-like peptide is appended at the C-terminus of the core peptide.17–20
Arnison et al. Page 60
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
A. Structure of nisin A. Dha residues are shown in green, Dhb residues in purple. Segments
of Lan and MeLan originating from Ser/Thr are depicted in red and segments of (Me)Lan
originating from Cys in blue. B. Biosynthetic pathway to (Me)Lan and labionin formation.
Ser and Thr residues are first phosphorylated and the phosphate is subsequently eliminated
to generate Dha and Dhb residues, respectively. Phosphorylation prior to elimination has
been experimentally confirmed for class II–IV lanthipeptides and is postulated for class I
lanthipeptides. Subsequent intramolecular conjugate addition by the side chain of Cys
generates an enolate. Protonation of the enolate produces the (Me)Lan structures whereas
attack of the enolate onto another Dha generates the labionin crosslinks.
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Fig. 3.
Four different classes of lanthipeptides are defined by the four different types of biosynthetic
enzymes that install the characteristic thioether crosslinks. The dark areas show conserved
regions that are important for catalytic activity. The cyclase domain of class III enzymes104
has homology with the other cyclase domains/enzymes but lacks the three zinc ligands.
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Fig. 4.
Some representative lanthipeptides. The same shorthand notation is used as in Fig. 2.
Segments of crosslinks originating from Cys are in blue, segments originating from Ser/Thr
are in red. Additional post-translational modifications are shown in orange.138 OBu, 2-
oxobutyric acid; Asp-OH, (3R)-hydroxy-aspartate; Lys-NH-Ala, lysinoalanine.
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Fig. 5.
A. Structure of cypemycin, a representative member of the linaridins. The linear sequence of
the precursor peptide is shown below the retrosynthetic arrow to illustrate the biosynthetic
origin of each PTM: allo-Ile from Ile, Dhb from Thr, and AviCys from two Cys residues
(underlined). For comparison, the structure of the lanthipeptide epidermin, which also
contains an AviCys structure, is shown but its AviCys is formed from a Ser and Cys residue
(underlined). B. Chemical structure of AviCys as well as the shorthand notation used in
panel A; the absolute configuration of the AviCys and allo-Ile in cypemycin is not known.
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Fig. 6.
Structure of polytheonamide A and B and sequence of the precursor core region. The two
congeners differ by the configuration of the sulfoxide moiety. Sulfur oxidation is an artifact
occurring during isolation. Color code for posttranslations modifications: purple,
epimerization; green, dehydration; red, methylation; blue, hydroxylation.
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Fig. 7.
A. Proposed biosynthesis of the N-acyl unit of polytheonamides. The dehydration step was
experimentally verified. B. Polytheonamide biosynthetic gene cluster.
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Fig. 8.
LAP biosynthetic scheme and precursor peptide sequences. A, Upon recognition of the
precursor peptide (black line) by the heterocycle-forming BCD enzymatic complex, select
Cys and Ser/Thr undergo a backbone cyclodehydration reaction with a preceding amino
acid. Catalyzed by a cyclodehydratase (C/D-proteins, green and blue), net loss of water from
the amide carbonyl during this reaction yields an azoline heterocycle. Further processing by
a FMN-dependent dehydrogenase (B-protein, yellow) affords the aromatic azole
heterocycle. B, Amino acid sequence of several LAP precursors. Like most RiPPs, these
consist of a leader peptide (to facilitate recognition by the modifying enzymes) and core
region that encodes for the resultant natural product. From top to bottom are the LAP
precursors for SLS, microcin B17, goadsporin, and plantazolicin. Post-translational
modifications are color-coded (Cys resulting in thiazoles, red; Ser/Thr resulting in oxazoles
and methyloxazoles, blue; Thr leading to methyloxazoline, brown; Ser converted to
dehydroalanine, light blue; N-terminal acetylated/methylated residues, green). The leader
peptide cleavage site is indicated with a dash (predicted for SLS).
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Fig. 9.
Representative structures of LAPs. Microcin B17 is a DNA gyrase inhibitor (antibiotic),
goadsporin induces secondary metabolism and morphogenesis in actinomycetes, and
plantazolicin is a selective antibiotic with an unknown biological target. Color coding as in
Fig. 8.
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Fig. 10.
Representative cyanobactins. Anacyclamide is modified only by N–C cyclization, while
others are modified by heterocyclization of Cys (yellow) or Ser/Thr (blue), oxidation to
azole (red dashed line), prenylation (pink) or N-methylation (green).
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Fig. 11.
Generalized biosynthesis of cyanobactins that contain azoline heterocycles. Translation of
the core peptide is followed by heterocyclization, then proteolytic tailoring to yield
macrocycles. RS = recognition sequence, essential for proteolytic tailoring. Multiple copies
of core peptide + recognition sequences are possible; here an example is shown in which a
single core peptide exists and is modified (n = 0). Other tailoring, such as prenylation,
probably takes place on the mature cycle, while the timing of oxidation/dehydrogenation to
azoles is not known. Additional modifications are also sometimes present.185 Oxi =
thiazoline oxidase, N-pro and C-pro are the protease domains that cleave the N-terminus and
C-terminus of the core peptides, respectively, and DUF are domains of unknown function.
C-pro also performs macrocyclization (Cyc).
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Fig. 12.
A. Representative thiopeptide structures. The central dehydropiperidine or pyridine rings are
in blue, the thiazole and thiazoline rings are in red, and the Dha and Dhb residues are in
green. B. The structural series of thiopeptides, showing the typical substitution pattern of the
central nitrogenous heterocycle.
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Fig. 13.
Bycroft proposal for generation of the pyridine ring in thiopeptides from two Dha residues.
The aromatization step would also remove the leader peptide.50
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Fig. 14.
Structures of various bottromycins.
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Fig. 15.
Potential biosynthetic pathway to bottromycin A2. The order of the posttranslational
modifications is currently not known and hence the order depicted is arbitrary. The
precursor peptide sequences for the currently known bottromycins are shown at the top.
Variations in the posttranslational modifications morph these precursor sequences into the
structures shown in Fig. 14.
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Fig. 16. Structures of the post-translationally modified microcins
A. Structures of several class I microcins. Both the linear sequence and three dimensional
structure of microcin J25 is shown (PDB 1Q71). Microcin B17, another class I microcin, is
shown in Fig. 9. B. Class II microcins. The post-translational modifications of class IIb
microcins attach a linear trimer of 2,3-dihydroxybenzoyl L-serine linked via a C-glycosidic
linkage to a β-D-glucose. The glucose is anchored to the carboxylate of the C-terminal
serine residues of the peptides (red font) through an ester linkage to O6.
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Fig. 17. Structural features of lasso peptides
A) Sequences of lasso peptides of the three classes showing the residues involved in the
macrolactam in green and those forming the tail in blue. The isopeptide linkage between the
N-terminal amino group and the side chain carboxylates of Asp and Glu are shown in dark
green. B) Three-dimensional structures of lasso peptides of the three classes; the structures
of the class II microcin J25 and capistruin exhibit the respective sizes of the loop and tail
above and below the ring.
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Fig. 18. Structures of microviridin B from M. aeruginosa NIES298 and mar-inostatin 1-12 from
Alteromonas sp. B-10-31. 322,325
Amino acid side chains forming ester and amide bonds are highlighted in red and blue,
respectively.
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Fig. 19.
Sequences of sactipeptides based on structural genes. The arrow indicates the site of
cleavage of the N-terminal leader peptide. Subtilosin A and SKF are then cyclized via an
amide bond between the amino group of residue 1 and the C-terminal carboxyl. The other
peptides are not cyclized in this fashion, but all have cysteine residues linked to α-carbons.
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Fig. 20.
Three dimensional solution structures of sactipeptides. Subtilosin A has S to Cα crosslinks
between C4 and F31, C7 and T28, and C13 and F22. Thurincin H has such links between C4
and S28, C7 and T25, C10 and T22, and C13 and N19. Trn-α has links between C5 and T28,
C9 and T25, and C13 and S21. Trn-β has links between C5 and Y28, C9 and A25, and C13
and T21. SKF (not shown, 3D structure not reported) has a single S to Cα crosslink between
C4 and M12. It also has a disulfide bond between C1 and C16.
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Fig. 21.
Comparison of the sequences of some cyclic bacteriocins based on the structural genes. The
arrow indicates the cleavage site for the N-terminal leader, whose removal is followed by
amide bond formation between the amino group of residue 1 and the carboxyl of the C-
terminal residue.
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Fig. 22.
Comparison of the three dimensional structures of enterocin AS-48 (blue) and carnocyclin A
(magenta). (A) Sequence comparison with helices and loop indicated. (B) Overlay of
backbones of the two peptides showing the saposin fold and similarities in structure. (C)
Ribbon diagrams for the two peptides.
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Fig. 23.
Comparison of gene clusters for biosynthesis of large ring bacteriocins.
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Fig. 24.
A. Chemical structures of a representative amatoxin and phallotoxin. B. Alignment of a
select number of precursor peptides illustrating the highly conserved leader peptide and
recognition sequences in red. The core peptide that is post-translationally modified, excised,
and cyclized is shown in blue font. For beta-amanitin and phalloidin, the sequences are from
genomic DNA whereas the other two sequences are from cDNA. Because of an intron in the
genomic DNA, the last three amino acids of the recognition sequence are not known with
certainty for beta-amanitin and phalloidin and are represented with dashes.
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Fig. 25. Structure of kalata B1 and cyclotide precursor proteins
A schematic representation of three precursor proteins from O. affinis is shown at the top of
the figure. The proteins comprise an endoplasmic reticulum signal sequence labeled ER, a
leader sequence (comprising a pro-region and a conserved repeated fragment labeled NTR)
and either one or multiple copies of the core peptides. A short hydrophobic C-terminal
recognition sequence is present in each precursor. At the bottom of the figure the amino acid
sequence of kalata B1 is shown, with the cysteine residues labeled with Roman numerals.
The cleavage sites for excision of a core cyclotide domain with an N-terminal Gly and a C-
terminal Asn, which are thought to be subsequently linked by an asparaginyl endopeptidase,
are indicated by arrows. The location of the ligation point, which forms loop 6 of the mature
cyclic peptide, is shown on the right. Parts of the precursor protein flanking the mature
domain are shown in lighter shading. Figure reprinted with permission from Daly et al.379
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Fig. 26.
Structures of segetalins containing six and seven amino acids, isolated from Vaccaria
segetalis (Caryophyllaceae).406
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Fig. 27.
Amino acid sequences of cyclic peptides arising from Linaceae species Linum
usitatissimum. The RiPP core peptides putatively encoding cyclolinopeptides D, F, and G is
shown in blue, green, and red, respectively, with putative recognition sequences shown in
pink and underlined font.
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Fig. 28.
Structures of three post-translationally modified conopeptides that reached human clinical
trials.
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Fig. 29. Structures of two glycocins
The precursor peptide that is transformed into sublancin by disulfide formation and S-
glycosylation is shown below the sublancin 168 structure.
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Fig. 30.
A. Structure of AIP-I and the ribosomally synthesized precursor peptide from which it is
produced. B. Structures of ComX and its derivatives and the ribosomally synthesized
precursor peptides from which they are produced. The red font Trp is converted to the
structure shown by cyclization of the amide nitrogen of Trp onto C2 of the indole and
prenylation at C3. After leader peptide removal, the modified Trp is present in short peptides
with the sequences of R1 and R2 shown in blue font.
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Fig. 31.
Currently accepted structure of methanobactin from M. trichosporium OB3b and the
precursor peptide from which it may be derived.
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Fig. 32.
Structures of (A) PQQ, (B) coelenterazine, (C) the pantocins, and (D) the thyroid hormones
T3 and T4. For PQQ and the pantocins, the ribosomally synthesized precursor peptides from
which they are produced are also depicted.
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Fig. 33. Select examples of the linear description of RiPPs
The linear description is shown above each chemical structure. The 3–4 character
descriptors are shown in bold red font, the amino acids to which they refer are shown in
non-bold red font. Abu, 2-aminobutyric acid.
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Fig. 34.
Additional examples of linear shorthand notation for RiPPs.
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Table 1
Proposed nomenclature for RiPP biosynthesis
Nomenclature proposed herein Previous designations
Precursor peptide Prepeptide (lantibiotics, microviridins) Prepropeptide
(lantibiotics, cyclic
bacteriocins)
Structural peptide (translation
product of the structural gene;
lantibiotics, thiopeptides)
Leader peptide Propeptide (microcins, conopeptides,
cyclotides)
Pro-region (conopeptides) Intervening region (conopeptides)
Core peptide Propeptide (lantibiotics, mycotoxins,
cytolysins, cyclic bacteriocins)
Structural peptide
(lantibiotics, thiopeptides,
cyanobactins)
Toxin region (conopeptides)
Recognition sequences NTR, N-terminal repeats (cyclotides)
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Table 2
Predicted amino acid sequences of cyclic peptides from Caryophyllaceae and Rutaceae
Leader Core peptidea Recognition sequenceb Name
Caryophyllaceae
− 1 1 + 1
MSPILAHDVVKPQ GVPVWA FQAKDVENASAPV A1
MSPILAHDVVKPQ GVAWA FQAKDVENASAPV B1
MSPIFAHDVVNPQ GLSFAFP  AKDAENASSPV D1
MSPIFAHDVVKPQ GLSFAFP  AKDAENASSPV D2
MSPILAHDVVKPQ GLSFAFP  AKDAENASSPV D3
MSPIFVHEVVKPQ GVKYA FQPKDSENASAPV G1
MSPIFAHDIVKPK GYRFS FQAKDAENASAPV H1
MSPILALDRYKPE GRVKA FQAKDAENASAPV K1
MSPILSHDVVKPQ GLPGWP FQAKDVENASAPV L1
MATSFQFDGLKPS FSASYSSKP IQTQVSNGMDNASAPV F1
MATSFQLDGLKPS FGTHGLPAP IQVPNGMDDACAPM J1
MSPNSTRDLLKPL GYKDCC FQAKDLENAAVPV CF259529
MSPNSTRDILKPQ GPIPFYG FQAKDAENASVPV AW697819
MSPNSTLDILKPL GLPYEQ FQAKDSENASAPV AW697902
MSPISAHDQLIPH GLVCPPLCP FQAKDSENAAVPV JK743966
MXPTVAHNMLKPH GSIFFS FQAKDAENXSAPV JK743974
Rutaceae
− 1 1 + 1
METTCAGNNW SE GLLLPPFG SIADDDVMND NLDFLNVPQYGRNPDYMG
MKTLAGAGMSDPSE GLVLPS SIADDDVGND NLDLIVIPQYGRNPDYYG
MKTLPGAGMSDPSE GYLLPPS SIADDDVGND NLDLIVIPQYGRNPDYYG
MKIMETTCAGNDDCLE GRPWNLA SIVDDNVANDVNLDLLAVPQYGRNTDQTG
MKNMETTSAGNDDWLE GYVAA SIVDDNIANDVNLDLLTVPQYGRNIDQTG
MKNMETTCAGNDDWLE GAPWLIAA SIVDDNIANDVNLDLLTVPQYGRNIDQTG
MKNMETTSAGNADWLE GVPWAIAA SIVDDNIANDVNLDLLTVPQYGRNIDQTG
a
Products of bolded core peptides have been observed by MS/MS.
bAmino acid X reflects a stop codon within the sequence.
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Table 3
Predicted amino acid sequence of Jatropha cyclic peptides based on genome sequences identified in Genbank.
The sequences corresponding to curcacyclines A and B are shown in red font
BABX01100257.1 (3315–3349) MAVSPIQSVLGMLGVMSMQQRQAGVNISSFYPPVAQ ILGSPILLG
BABX01004419.1 (3001–2870) MAVSPIQSVLGMLGVMSTAQRQTGVNISSFYPPVAQ LLGTVL-LG
BABX01106530.1 (407–535) MAVSPIQSVLGMLGIMSMQHRHAGVHISSFYPPVAQ VWNSWFN–
Consensus MAVSPIQSVLGMLG-MS---R--GV--SSFYPPVAQ -------
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Table 4
Modifications of amino acid residues found in conopeptides
Modification Amino acid residue Final product
C-terminal amidation Glycine C-terminal –CO–NH2
N-terminal cyclization Glutamine N-terminal pyroglutamate
Hydroxylation Proline; Valine; Lysine 4-Hydroxyproline; D-γ hydroxyvaline; 5-hydroxylysine
Carboxylation Glutamate γ-Carboxyglutamate
Sulfation Tyrosine Sulfotyrosine
Bromination Tryptophan 6-Bromotryptophan
Oxidation Cysteine Disulfide bridge
Glycosylation Threonine Various O-glycosyl amino acids
Epimerization Valine; Leucine; Phenylalanine; Tryptophan D-Valine; D-leucine; D-phenylalanine; D-tryptophan
Proteolysis Various Mature conopeptides
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Table 5
Designations for some of the post-translational modifications found in RiPPs that allow their description in
linear format. Some examples are shown in Fig. 33 and 34. This list is not a comprehensive listing of all PTMs
found in RiPPs
PTM Shorthand notation
Structures and examples from
this review Figure Occurrence
Single residue modifications
2,3-Dehydroamino acid Δαβ dehydroalanine Lanthipeptides, LAPs, thiopeptides
dehydrobutyrine
nisin 2/33
lacticin 3147 4
goadsporin 9
thiostrepton A 12
nosiheptide 12
thiomuracin 12
O-Phosphorylation of Ser/Thr
Descarboxy
OβP pSer, pThr 2 Lanthipeptides
ΔCO2 decarboxylated C-terminal
residue gallidermin
33 Lanthipeptides, linaridins, thiopeptides
epidermin 5
cypemycin 5
micrococcin P1 12
Cβ-hydroxylation CβOH e.g. β-hydroxy-Asp duramycin 4 Lanthipeptides, proteusins
e.g. β-hydroxy-Val, β-hydroxy-
Asn polytheonamide A
6
Cγ-hydroxylation CγOH e.g. γ-hydroxy-Pro α-amanitin 24/34 Lanthipeptides, conopeptides,
phallotoxins, amatoxins
MrIA 28
e.g. γ-hydroxy-Leu/Ile phalloidin 24 Phallotoxins, orbitides
Cδ-hydroxylation CδOH e.g. δ-hydroxy-Ile α-amanitin 24/34 Amatoxins, orbitides, conopeptides
Amatoxins
Aromatic ring hydroxylation C6OH e.g. C6 hydroxy-Trp α-amanitin 24/34
Cγ-carboxylation CγCO2 Glu carboxylation conantokin-G 28 Conopeptides
Cβ-methylation CβMe e.g. β-methyl-Val 6 Proteusins, bottromycins
polytheonamides bottromycin A2 14
e.g. β-methyl-Pro, β-methyl-Phe
bottromycin A2
14
e.g. β-methyl-Met polytheonamide 6
N-terminal acetylation NαAc goadsporin 9 Lanthipeptides, microviridins
microviridin B 18/33
N-terminal mono or dimethylation NαMe Linaridins, LAPs, orbitides
NαMe2 cypemycin 5
plantazolicin 9
N-terminal pyroglutamate formation NαCδanhydro contulakin-G 28
MrIA 28
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PTM Shorthand notation
Structures and examples from
this review Figure Occurrence
Glycosylation Cys, Thr and Ser glycosylation Glycocins, conopeptides
SβGlc sublancin 29/34
SβGlcNAc glycocin F 29/34
OβGlcNAc glycocin F 29
OαGalNAc GalNAc-Thr, contulakin-G 28
Epimerization 2R D-Ala in lacticin 3147 4 Nearly all compound classes discussed
in this review
polytheonamides 6
C-terminal amidationa CONH2 conantokin-G 28 Conopeptides, thiopeptides
nosiheptide 12
thiostrepton A 12
Crosslink of two residues
Disulfide SS labyrinthopeptin 4/33 Lanthipeptides, cyanobactins,
cyclotides, lasso peptides,
conopeptides, glycocins, sactipeptides
ulithiacyclamide 10
siamycins 17
kalata B1 25/34
MrIA 28
sublancin 29/34
glycocin F 29
Lanthionine SCβ or CβSb thioether nisin 2 Lanthipeptides
actagardine 4
duramycin 4
lacticin 3147 4
SapT 4
Lanthionine sulfoxide S(O)Cβ actagardine 4 Lanthipeptides
Lysinoalanine NεCβ secondary amine duramycin 4 Lanthipeptides
α-carbon to β-carbon CαCβ labionin labyrinthopeptin 4/33 Lanthipeptides
Oxazole Oxz microcin B17 9 LAPs, cyanobactins, thiopeptides
Oxazoline OxH patellamide A 10 LAPs, cyanobactins, thiopeptides
Methyloxazole MeOxz plantazolicin 9/33 LAPs, cyanobactins
goadsporin 9
microcyclamide 10
Methyloxazoline MeOxH plantazolicin 9/33 LAPs, cyanobactins
patellamide A 10
patellamide C 33
Thiazole Thz microcin B17 9 LAPs, cyanobactins, thiopeptides,
bottromycins
goadsporin 9
plantazolicin 9/33
patellamide A 10
patellamide C 33
Nat Prod Rep. Author manuscript; available in PMC 2014 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Arnison et al. Page 100
PTM Shorthand notation
Structures and examples from
this review Figure Occurrence
microcyclamide 10
trichamide 10
bottromycin A2 14
Thiazoline ThH trunkamide 10 LAPs, cyanobactins, thiopeptides
Tryptathionine C2S or SC2b thioether phalloidin 24 Phallotoxins
Tryptathionine sulfoxide C2S(O) α-amanitin 24/34 Amatoxins
α-carbon linked to sulfur SCα (or CαS)b thioether subtilosin 20/34 Sactipeptides, thiopeptides
thuricin CD 20
C- to N-terminal cyclization NαC patellamide A 10 Cyanobactins, amanitins, cyclotides,
orbitides, sactipeptides
patellamide C 33
subtilosin 20/34
enterocin AS-48 22
carnocyclin A 22
α-amanitin 24/34
kalata B1 34
cyclolinopeptides 27
segetalins 26
N-terminal amine and Glu/Asp side
chain N-terminal amine and Glu/
Asp side chain peptide tail goes
through the lactam
NαCδ isopeptide
NαCγ
NαCd@ siamycin 17 Lasso peptides
NαCγ@ capistruin 17/34
microcin J25 16
Indication of size of peptide tail
through lactam Lys side chain with
Glu side chain
NαCδ–@[9–21] microcin J25 17 Lasso peptides
NαCγ–@[10–19] capistruin 34
CδNε or NεCδb isopeptide microviridin B 18/33 Microviridins
Lys side chain with Asp side chain NεCγ or CγNεb isopeptide Microviridins
Asp side chain with Ser/Thr: CγOβ or OβCγb ester Microviridins
microviridin B 18/33
marinostatin 1–12 18
Glu side chain with Ser/Thr: CδOβ or OβCδb ester Microviridins
microviridin B 18/33
Cys side chain and C-terminal
carboxylate
SβCO thioester AIP-I 30 AIPs
a
In many cases, amidation of the C-terminus may be better described as cleavage of the bond between the amide nitrogen and the α-carbon of what
was the C-terminal amino acid.
b
The peptide sequence determines which of the two possible notations should be used. For instance, a lanthionine formed from Cys1 and Ser2
would be SCβ whereas a lanthionine formed from Ser1 and Cys2 would be CβS.
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